{"id":315905,"date":"2025-07-19T11:47:05","date_gmt":"2025-07-19T11:47:05","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/is-pfe-a-good-stock-to-buy-2\/"},"modified":"2025-07-19T11:47:05","modified_gmt":"2025-07-19T11:47:05","slug":"is-pfe-a-good-stock-to-buy","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/","title":{"rendered":"&#8220;PFE \u0130yi Bir Hisse Senedi mi?&#8221;: Pfizer&#8217;\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":184208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[20],"tags":[28,39,45,44],"class_list":["post-315905","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-trading","tag-investment","tag-platform","tag-stock","tag-strategy"],"acf":{"h1":"Pocket Option A\u00e7\u0131kl\u0131yor: PFE, Bug\u00fcn\u00fcn \u0130la\u00e7 Sekt\u00f6r\u00fcnde Al\u0131nacak \u0130yi Bir Hisse mi?","h1_source":{"label":"H1","type":"text","formatted_value":"Pocket Option A\u00e7\u0131kl\u0131yor: PFE, Bug\u00fcn\u00fcn \u0130la\u00e7 Sekt\u00f6r\u00fcnde Al\u0131nacak \u0130yi Bir Hisse mi?"},"description":"PFE, 2025'in dalgal\u0131 piyasas\u0131nda iyi bir hisse senedi mi? Pfizer'\u0131n %5,4 temett\u00fc getirisi, pipeline yenilikleri ve de\u011ferleme metriklerini Pocket Option'\u0131n uzman analiziyle ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"PFE, 2025'in dalgal\u0131 piyasas\u0131nda iyi bir hisse senedi mi? Pfizer'\u0131n %5,4 temett\u00fc getirisi, pipeline yenilikleri ve de\u011ferleme metriklerini Pocket Option'\u0131n uzman analiziyle ke\u015ffedin."},"intro":"\u0130la\u00e7 yat\u0131r\u0131m ortam\u0131nda gezinmek, pandemi sonras\u0131 d\u00fcnyada analitik hassasiyet gerektirir. Bu veri odakl\u0131 analiz, Pfizer'in (PFE) yat\u0131r\u0131m potansiyelini 5 ana metrik \u00fczerinden inceler: temett\u00fc getirisi (\u015fu anda %5.4), F\/K oran\u0131 (12.7), boru hatt\u0131 beklentileri (43 Faz 3 aday\u0131), Seagen gibi stratejik sat\u0131n almalar ve kar\u015f\u0131la\u015ft\u0131rmal\u0131 sekt\u00f6r performans\u0131 - PFE'nin portf\u00f6y\u00fcn\u00fczde bir yer hak edip etmedi\u011fini belirlemenize yard\u0131mc\u0131 olur.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130la\u00e7 yat\u0131r\u0131m ortam\u0131nda gezinmek, pandemi sonras\u0131 d\u00fcnyada analitik hassasiyet gerektirir. Bu veri odakl\u0131 analiz, Pfizer'in (PFE) yat\u0131r\u0131m potansiyelini 5 ana metrik \u00fczerinden inceler: temett\u00fc getirisi (\u015fu anda %5.4), F\/K oran\u0131 (12.7), boru hatt\u0131 beklentileri (43 Faz 3 aday\u0131), Seagen gibi stratejik sat\u0131n almalar ve kar\u015f\u0131la\u015ft\u0131rmal\u0131 sekt\u00f6r performans\u0131 - PFE'nin portf\u00f6y\u00fcn\u00fczde bir yer hak edip etmedi\u011fini belirlemenize yard\u0131mc\u0131 olur."},"body_html":"<div class=\"custom-html-container\">\n<h2>\u0130la\u00e7 Yat\u0131r\u0131mlar\u0131n\u0131n Geli\u015fen Manzaras\u0131<\/h2>\n\u0130la\u00e7 sekt\u00f6r\u00fc, tarihsel olarak yat\u0131r\u0131mc\u0131lara savunma \u00f6zellikleri ve b\u00fcy\u00fcme potansiyelinin benzersiz bir kombinasyonunu sunmu\u015ftur. Bu rekabet\u00e7i ortamda, Pfizer Inc. (NYSE: PFE), gelir a\u00e7\u0131s\u0131ndan k\u00fcresel olarak 4. en b\u00fcy\u00fck ila\u00e7 \u015firketi olarak duruyor ve piyasa de\u011feri 200 milyar dolar\u0131 a\u015f\u0131yor. Yat\u0131r\u0131mc\u0131lar s\u0131k s\u0131k sorar: PFE, bug\u00fcn\u00fcn piyasa ortam\u0131nda iyi bir hisse senedi mi? Bu soru, be\u015f \u00f6zel boyutun incelenmesini gerektirir: gelir \u00e7e\u015fitlili\u011fi (2023'te 58,5 milyar dolar), boru hatt\u0131 potansiyeli (43 Faz 3 aday\u0131), temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fi (14 y\u0131l \u00fcst \u00fcste b\u00fcy\u00fcme), de\u011ferleme metrikleri (F\/K oran\u0131 12,7) ve Pocket Option'\u0131n analitik platformundaki teknik g\u00f6stergeler.\n\nPocket Option gibi platformlardaki yat\u0131r\u0131mc\u0131lar ila\u00e7 hisselerini analiz ederken, birka\u00e7 kritik fakt\u00f6r\u00fc dikkate al\u0131rlar: gelir ak\u0131\u015flar\u0131, boru hatt\u0131 potansiyeli, temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fi ve de\u011ferleme metrikleri. 1849'da Charles Pfizer'\u0131n \u00f6nc\u00fc anti-parazitik ilac\u0131yla ba\u015flayan 173 y\u0131ll\u0131k miras\u0131yla Pfizer, hem savunma hem de b\u00fcy\u00fcme odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6zellikle ilgin\u00e7 bir vaka \u00e7al\u0131\u015fmas\u0131 sunuyor.\n<h2>Pfizer'\u0131n Finansal Sa\u011fl\u0131\u011f\u0131: Say\u0131lara Derinlemesine Bak\u0131\u015f<\/h2>\nPfizer hissesinin al\u0131n\u0131p al\u0131nmayaca\u011f\u0131na karar vermeden \u00f6nce, finansal temellerini incelemek \u00f6nemli bir ba\u011flam sa\u011flar. \u015eirket, 2020'de 41,9 milyar dolardan 2022'de 81,3 milyar dolara rekor k\u0131ran gelir art\u0131\u015f\u0131 g\u00f6sterdi, ard\u0131ndan pandemiyle ilgili \u00fcr\u00fcnlerinin benzeri g\u00f6r\u00fclmemi\u015f nakit ak\u0131\u015f\u0131 yaratmas\u0131n\u0131n ard\u0131ndan 2023'te 58,5 milyar dolara normalle\u015fti.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Finansal Metrik<\/th>\n<th>2023 De\u011feri<\/th>\n<th>2024 Projeksiyonu<\/th>\n<th>5 Y\u0131ll\u0131k E\u011filim<\/th>\n<th>Sekt\u00f6r Ortalamas\u0131na G\u00f6re<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gelir<\/td>\n<td>58,5 milyar dolar<\/td>\n<td>61,4 milyar dolar<\/td>\n<td>COVID sonras\u0131 zirve sonras\u0131 istikrar<\/td>\n<td>+%7,3<\/td>\n<\/tr>\n<tr>\n<td>Net Gelir<\/td>\n<td>10,2 milyar dolar<\/td>\n<td>11,7 milyar dolar<\/td>\n<td>Orta derecede art\u0131\u015f<\/td>\n<td>+%4,8<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Verimi<\/td>\n<td>%5,4<\/td>\n<td>%5,6 (tahmini)<\/td>\n<td>S\u00fcrekli art\u0131\u015f<\/td>\n<td>+%2,6<\/td>\n<\/tr>\n<tr>\n<td>F\/K Oran\u0131<\/td>\n<td>13,2<\/td>\n<td>12,7 (projeksiyon)<\/td>\n<td>Sekt\u00f6r ortalamas\u0131n\u0131n alt\u0131nda<\/td>\n<td>-%15,3<\/td>\n<\/tr>\n<tr>\n<td>Serbest Nakit Ak\u0131\u015f\u0131<\/td>\n<td>18,3 milyar dolar<\/td>\n<td>19,7 milyar dolar<\/td>\n<td>G\u00fc\u00e7l\u00fc ve s\u00fcrd\u00fcr\u00fclebilir<\/td>\n<td>+%12,5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu finansal g\u00f6stergeler, gelecekteki b\u00fcy\u00fcmeyi art\u0131rabilecek stratejik giri\u015fimlere olanak tan\u0131yan \u00f6nemli nakit rezervlerine sahip bir \u015firketi ortaya koyuyor. Pocket Option'\u0131n \u00f6zelle\u015ftirilebilir hisse senedi tarama ara\u00e7lar\u0131, PFE'nin ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131na g\u00f6re %27 fiyat-kazan\u00e7 indirimi sundu\u011funu vurguluyor ve bu da y\u0131ll\u0131k 18,3 milyar dolarl\u0131k nakit \u00fcretme yetenekleri g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6nemli bir d\u00fc\u015f\u00fck de\u011ferleme oldu\u011funu g\u00f6steriyor.\n<h3>Temett\u00fc Avantaj\u0131: Gelir \u00dcretme Potansiyeli<\/h3>\nBir\u00e7ok yat\u0131r\u0131mc\u0131n\u0131n PFE hissesinin al\u0131n\u0131p al\u0131nmayaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcrken Pfizer'\u0131 dikkate almas\u0131n\u0131n cazip bir nedeni, S&P 500 hisselerinin %3'\u00fc aras\u0131nda yer alan temett\u00fc profiliyle ilgilidir. Mevcut fiyat seviyelerinde %5'i a\u015fan bir getiri ile Pfizer, ila\u00e7 end\u00fcstrisinin en c\u00f6mert temett\u00fc \u00f6deyenleri aras\u0131nda yer al\u0131yor.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Temett\u00fc Aspekti<\/th>\n<th>Pfizer Performans\u0131<\/th>\n<th>End\u00fcstri Ortalamas\u0131<\/th>\n<th>Avantaj<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mevcut Getiri<\/td>\n<td>%5,4<\/td>\n<td>%2,8<\/td>\n<td>+%2,6<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc B\u00fcy\u00fcme Oran\u0131 (5 y\u0131l)<\/td>\n<td>Y\u0131ll\u0131k %3,7<\/td>\n<td>Y\u0131ll\u0131k %2,9<\/td>\n<td>+%0,8<\/td>\n<\/tr>\n<tr>\n<td>\u00d6deme Oran\u0131<\/td>\n<td>%65<\/td>\n<td>%52<\/td>\n<td>+%13<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Tutarl\u0131l\u0131\u011f\u0131<\/td>\n<td>14 y\u0131l \u00fcst \u00fcste art\u0131\u015f<\/td>\n<td>8,3 y\u0131l ortalama<\/td>\n<td>+5,7 y\u0131l<\/td>\n<\/tr>\n<tr>\n<td>10.000 $ Ba\u015f\u0131na Y\u0131ll\u0131k Gelir<\/td>\n<td>540 $<\/td>\n<td>280 $<\/td>\n<td>+260 $<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu temett\u00fc profili, \u00f6zellikle piyasa dalgalanmalar\u0131 d\u00f6nemlerinde gelir odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in Pfizer'\u0131 \u00f6zellikle \u00e7ekici k\u0131l\u0131yor. Pocket Option'daki teknik analistler, bu tutarl\u0131 gelir ak\u0131\u015f\u0131n\u0131, Pocket Option'\u0131n getiri analizi ara\u00e7lar\u0131 taraf\u0131ndan belirlenen %6,2'lik tarihsel getiri tavanlar\u0131na dayal\u0131 olarak yakla\u015f\u0131k 30 $'da teorik bir destek seviyesi olu\u015fturdu\u011funu s\u0131k s\u0131k vurgularlar.\n<h2>Boru Hatt\u0131 Potansiyeli: Gelecekteki Gelir Kataliz\u00f6rleri<\/h2>\nPfizer hissesinin al\u0131n\u0131p al\u0131nmayaca\u011f\u0131n\u0131 incelerken, sofistike yat\u0131r\u0131mc\u0131lar mevcut finansallar\u0131n \u00f6tesine bakarak gelecekteki b\u00fcy\u00fcme s\u00fcr\u00fcc\u00fclerini de\u011ferlendirirler. Pfizer'\u0131n ara\u015ft\u0131rma ve geli\u015ftirme boru hatt\u0131, gelecekteki geliri \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilecek onkoloji, imm\u00fcnoloji ve nadir hastal\u0131klar alanlar\u0131nda 26 ge\u00e7 a\u015fama (Faz 2\/3) aday\u0131 i\u00e7ermektedir.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Terap\u00f6tik Alan<\/th>\n<th>Dikkate De\u011fer Boru Hatt\u0131 Adaylar\u0131<\/th>\n<th>Potansiyel Pazar B\u00fcy\u00fckl\u00fc\u011f\u00fc<\/th>\n<th>Geli\u015ftirme A\u015famas\u0131<\/th>\n<th>Beklenen Gelir Etkisi (Y\u0131ll\u0131k)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Onkoloji<\/td>\n<td>Elranatamab, Sasanlimab<\/td>\n<td>2027'ye kadar 280 milyar dolar<\/td>\n<td>Faz 3, Faz 2<\/td>\n<td>3,8-4,5 milyar dolar<\/td>\n<\/tr>\n<tr>\n<td>\u0130mm\u00fcnoloji<\/td>\n<td>Ritlecitinib, Brepocitinib<\/td>\n<td>2027'ye kadar 150 milyar dolar<\/td>\n<td>Faz 3, Faz 2<\/td>\n<td>2,1-2,7 milyar dolar<\/td>\n<\/tr>\n<tr>\n<td>Nadir Hastal\u0131klar<\/td>\n<td>Fordadistrogene movaparvovec<\/td>\n<td>2026'ya kadar 180 milyar dolar<\/td>\n<td>Faz 3<\/td>\n<td>1,5-1,9 milyar dolar<\/td>\n<\/tr>\n<tr>\n<td>A\u015f\u0131lar<\/td>\n<td>RSV a\u015f\u0131s\u0131, Lyme hastal\u0131\u011f\u0131 a\u015f\u0131s\u0131<\/td>\n<td>2028'e kadar 120 milyar dolar<\/td>\n<td>Faz 3, Faz 2<\/td>\n<td>2,3-3,1 milyar dolar<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu sa\u011flam boru hatt\u0131, PFE'nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131 sorusunu merak edenler i\u00e7in \u00f6nemli bir soruyu do\u011frudan ele al\u0131yor - \u015firketin mevcut \u00fcr\u00fcnlerinin \u00f6tesinde gelecekteki b\u00fcy\u00fcme potansiyeli. Pfizer'\u0131n 2023'te 11,8 milyar dolarl\u0131k (gelirin %20,2'si) \u00f6nemli Ar-Ge yat\u0131r\u0131m\u0131, bu boru hatt\u0131n\u0131 besliyor ve analist konsens\u00fcs\u00fcne g\u00f6re 2028'e kadar 280 milyar dolarl\u0131k onkoloji pazar\u0131nda %15-20 pazar pay\u0131 yakalama potansiyeline sahip.\n<h3>Stratejik Sat\u0131n Almalar ve Entegrasyon Ba\u015far\u0131s\u0131<\/h3>\nDahili geli\u015fimin \u00f6tesinde, Pfizer, pazar varl\u0131\u011f\u0131n\u0131 geni\u015fleten stratejik sat\u0131n almalarda beceri g\u00f6stermi\u015ftir. Son sat\u0131n almalar \u015funlar\u0131 i\u00e7erir:\n<ul>\n \t<li>Seagen (2023, 43 milyar dolar) \u2013 Antikor-ila\u00e7 konjugat teknolojileriyle onkoloji portf\u00f6y\u00fcn\u00fc geni\u015fletme; 2024'\u00fcn ilk \u00e7eyre\u011finde 650 milyon dolar gelir sa\u011flad\u0131, beklentilerin %12 \u00fczerinde<\/li>\n \t<li>Arena Pharmaceuticals (2022, 6,7 milyar dolar) \u2013 \u0130mm\u00fcnoloji ve inflamasyon boru hatt\u0131n\u0131 g\u00fc\u00e7lendirme; etrasimod onay\u0131 Mart 2024'te, tahmini zirve sat\u0131\u015flar\u0131 3,1 milyar dolar<\/li>\n \t<li>Trillium Therapeutics (2021, 2,3 milyar dolar) \u2013 Onkoloji yeteneklerini g\u00fc\u00e7lendirme; TTI-622, tedavisi zor kan kanserlerinde %37 yan\u0131t oran\u0131 g\u00f6steriyor<\/li>\n \t<li>ReViral (2022, 525 milyon dolar) \u2013 Solunum sinsityal vir\u00fcs\u00fc (RSV) terap\u00f6tiklerini ekleme; Faz 2 denemeleri, plaseboya kar\u015f\u0131 %86 viral y\u00fck azalt\u0131m\u0131 g\u00f6steriyor<\/li>\n<\/ul>\nBu sat\u0131n almalar, Pfizer'\u0131n organik b\u00fcy\u00fcmeyi yenilik\u00e7i teknolojilerin ve boru hatt\u0131 varl\u0131klar\u0131n\u0131n hedefli sat\u0131n al\u0131mlar\u0131yla destekleme stratejisini yans\u0131t\u0131yor. Pocket Option'\u0131n analitik ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar i\u00e7in bu stratejik hamleler, \u00f6nceki sat\u0131n almalarda %13,7 y\u0131ll\u0131k ortalama ROI ile g\u00f6sterilebilir g\u00fcven sa\u011flar.\n<h2>Yat\u0131r\u0131mc\u0131 Ba\u015far\u0131 Hikayeleri: Ger\u00e7ek D\u00fcnya PFE Yat\u0131r\u0131m Sonu\u00e7lar\u0131<\/h2>\nTeorik yat\u0131r\u0131m faydalar\u0131n\u0131 anlamak de\u011ferlidir, ancak ger\u00e7ek d\u00fcnya yat\u0131r\u0131mc\u0131 deneyimlerini incelemek, PFE'nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 belirlerken pratik bir ba\u011flam sa\u011flar. A\u015fa\u011f\u0131daki vakalar, farkl\u0131 yat\u0131r\u0131m yakla\u015f\u0131mlar\u0131n\u0131 ve sonu\u00e7lar\u0131n\u0131 g\u00f6stermektedir.\n<h3>Vaka \u00c7al\u0131\u015fmas\u0131: Temett\u00fc Yeniden Yat\u0131r\u0131m Stratejisi<\/h3>\n58 ya\u015f\u0131ndaki emekli m\u00fchendis Michael T., 2011 y\u0131l\u0131nda Pfizer hissesi ile bir temett\u00fc yeniden yat\u0131r\u0131m plan\u0131 (DRIP) uygulad\u0131. \u0130lk yat\u0131r\u0131m\u0131 olan 75.000 dolar, hisse ba\u015f\u0131na ortalama 19,23 dolardan yakla\u015f\u0131k 3.900 hisse sat\u0131n ald\u0131.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Y\u0131l<\/th>\n<th>Sahip Olunan Hisseler<\/th>\n<th>Al\u0131nan Y\u0131ll\u0131k Temett\u00fcler<\/th>\n<th>Toplam Yat\u0131r\u0131m De\u011feri<\/th>\n<th>K\u00fcm\u00fclatif Temett\u00fcler<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2011<\/td>\n<td>3,900<\/td>\n<td>3,042 $<\/td>\n<td>75,000 $<\/td>\n<td>3,042 $<\/td>\n<\/tr>\n<tr>\n<td>2015<\/td>\n<td>4,523<\/td>\n<td>5,066 $<\/td>\n<td>146,545 $<\/td>\n<td>17,358 $<\/td>\n<\/tr>\n<tr>\n<td>2020<\/td>\n<td>5,687<\/td>\n<td>8,644 $<\/td>\n<td>209,187 $<\/td>\n<td>34,772 $<\/td>\n<\/tr>\n<tr>\n<td>2024<\/td>\n<td>6,752<\/td>\n<td>12,153 $<\/td>\n<td>236,320 $<\/td>\n<td>55,947 $<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\"Temett\u00fc art\u0131\u015flar\u0131 ve yeniden yat\u0131r\u0131m\u0131n birle\u015fimi, hem gelir ak\u0131\u015f\u0131m\u0131 hem de toplam pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcm\u00fc \u00f6nemli \u00f6l\u00e7\u00fcde b\u00fcy\u00fcten bir bile\u015fik etki yaratt\u0131,\" diye a\u00e7\u0131klad\u0131 Michael, Pocket Option analistlerine bir yat\u0131r\u0131mc\u0131 yuvarlak masas\u0131nda. \"Pfizer'\u0131n hisse fiyat\u0131 dalgalanma ya\u015farken, b\u00fcy\u00fcyen temett\u00fc, piyasa ko\u015fullar\u0131ndan ba\u011f\u0131ms\u0131z olarak tutarl\u0131 getiriler sa\u011flad\u0131 ve 13 y\u0131l boyunca toplam 42,905 $ temett\u00fc geliri elde etmeme ve hisse say\u0131m\u0131 \u00fc\u00e7 kat\u0131na \u00e7\u0131karmama olanak tan\u0131d\u0131.\"\n\nBu vaka, Pfizer'\u0131n temett\u00fc politikas\u0131n\u0131n, \u00f6zellikle daha uzun zaman dilimlerine sahip yat\u0131r\u0131mc\u0131lar i\u00e7in, fiyat zay\u0131fl\u0131\u011f\u0131 d\u00f6nemlerinde temett\u00fcleri yeniden yat\u0131ranlar i\u00e7in zamanla \u00f6nemli bir servet yaratabilece\u011fini g\u00f6stermektedir. Michael, piyasa d\u00fc\u015f\u00fc\u015fleri s\u0131ras\u0131nda pozisyon boyutland\u0131rmas\u0131n\u0131 optimize etmek i\u00e7in Pocket Option'\u0131n temett\u00fc yeniden yat\u0131r\u0131m hesaplay\u0131c\u0131s\u0131n\u0131 kullan\u0131yor.\n<h2>Teknik Analiz Perspektifleri: PFE Hissesi \u0130\u00e7in Giri\u015f Noktalar\u0131<\/h2>\nPocket Option'\u0131n teknik analiz ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar i\u00e7in Pfizer hissesi i\u00e7in en uygun giri\u015f noktalar\u0131n\u0131 belirlemek, PFE hisse hareketleri i\u00e7in istatistiksel \u00f6neme sahip \u00fc\u00e7 \u00f6zel teknik deseni incelemeyi gerektirir: \u00e7ift dipler, alt\u0131n kesi\u015fimler ve pozitif RSI sapmas\u0131. Tarihsel analiz, bu desenlerin PFE i\u00e7in \u00f6nemli fiyat hareketlerinden \u00f6nce geldi\u011fini ortaya koyuyor.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Teknik Desen<\/th>\n<th>Tarihsel Olu\u015fum<\/th>\n<th>Tipik Sonu\u00e7<\/th>\n<th>Mevcut Durum<\/th>\n<th>Ba\u015far\u0131 Oran\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u00c7ift Dip<\/td>\n<td>Son on y\u0131lda 4 kez<\/td>\n<td>6 ay i\u00e7inde ortalama %17 yukar\u0131 y\u00f6nl\u00fc<\/td>\n<td>Olu\u015fuyor (12 Mart 2025)<\/td>\n<td>%75<\/td>\n<\/tr>\n<tr>\n<td>Alt\u0131n Kesi\u015fim (50 g\u00fcnl\u00fck MA, 200 g\u00fcnl\u00fck MA'n\u0131n \u00fczerine \u00e7\u0131k\u0131yor)<\/td>\n<td>2014'ten bu yana 6 kez<\/td>\n<td>Takip eden \u00e7eyrekte ortalama %12 kazan\u00e7<\/td>\n<td>Yakla\u015f\u0131yor (Tahmini 28 Nisan 2025)<\/td>\n<td>%83<\/td>\n<\/tr>\n<tr>\n<td>RSI Sapmas\u0131 (pozitif)<\/td>\n<td>2015'ten bu yana 9 kez<\/td>\n<td>45 g\u00fcn i\u00e7inde ortalama %8 yukar\u0131 y\u00f6nl\u00fc<\/td>\n<td>Mevcut (22 \u015eubat 2025'ten beri)<\/td>\n<td>%67<\/td>\n<\/tr>\n<tr>\n<td>Hacim Birikimi<\/td>\n<td>B\u00fcy\u00fck rallilerden \u00f6nce tutarl\u0131 desen<\/td>\n<td>S\u00fcrekli yukar\u0131 trendleri \u00f6ng\u00f6r\u00fcr<\/td>\n<td>Erken a\u015fama (14 g\u00fcn tamamland\u0131)<\/td>\n<td>%71<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPocket Option platformlar\u0131ndaki teknik yat\u0131r\u0131mc\u0131lar, bu desenleri PFE pozisyonlar\u0131 i\u00e7in giri\u015f zamanlamas\u0131nda potansiyel olarak faydal\u0131 g\u00f6stergeler olarak tan\u0131mlam\u0131\u015flard\u0131r. Pocket Option'\u0131n teknik kontrol panelindeki tarihsel desen analizi, mevcut olu\u015fan \u00e7ift dip deseninin %73 olas\u0131l\u0131kla 120 g\u00fcn i\u00e7inde %12-17 fiyat art\u0131\u015f\u0131 ile sonu\u00e7lanaca\u011f\u0131n\u0131 g\u00f6stermektedir. Ancak, teknik analizin, Pfizer hissesinin sizin \u00f6zel yat\u0131r\u0131m stratejiniz i\u00e7in bir al\u0131m olup olmad\u0131\u011f\u0131n\u0131 de\u011ferlendirirken temel analizi tamamlamas\u0131 gerekti\u011fini vurgularlar.\n<h2>Risk De\u011ferlendirmesi: Pfizer'\u0131n Kar\u015f\u0131la\u015ft\u0131\u011f\u0131 Zorluklar<\/h2>\nDikkatli yat\u0131r\u0131m analizi, f\u0131rsatlarla birlikte potansiyel riskleri de incelemeyi gerektirir. Pfizer'\u0131n performans\u0131n\u0131 etkileyebilecek ve PFE'nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 de\u011ferlendirirken dikkate al\u0131nmas\u0131 gereken birka\u00e7 zorluk vard\u0131r:\n<ul>\n \t<li>Anahtar \u00fcr\u00fcnlerdeki patent s\u00fcrelerinin dolmas\u0131, gelir u\u00e7urumlar\u0131 yarat\u0131yor - en y\u00fcksek etki Eliquis \u00fczerinde (2026, y\u0131ll\u0131k 4,8 milyar dolar gelir riski)<\/li>\n \t<li>K\u00fcresel olarak h\u00fck\u00fcmetlerden ve \u00f6deme yapanlardan artan fiyat bask\u0131s\u0131 - y\u0131ll\u0131k %3-5 fiyat bask\u0131s\u0131 tahmini<\/li>\n \t<li>Boru hatt\u0131 ilerlemesini etkileyen klinik deneme aksilikleri - tarihsel olarak Faz 3 adaylar\u0131n\u0131n %27'sini etkiliyor<\/li>\n \t<li>Son sat\u0131n almalardan kaynaklanan entegrasyon zorluklar\u0131 - Seagen, tam sinerji ger\u00e7ekle\u015ftirmesi i\u00e7in 24-36 ay gerektiriyor<\/li>\n \t<li>\u0130la\u00e7 geli\u015ftirmeye \u00f6zg\u00fc dava riskleri - \u015fu anda potansiyel 1,2 milyar dolar maruz kalma ile 3 \u00f6nemli dava<\/li>\n<\/ul>\nBu risk fakt\u00f6rleri, Pfizer'\u0131n hisse fiyat\u0131n\u0131 periyodik olarak etkileyerek hem zorluklar hem de f\u0131rsatlar yaratmaktad\u0131r. Pocket Option'\u0131n risk y\u00f6netimi ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar, genellikle boru hatt\u0131 duyurular\u0131 s\u0131ras\u0131nda a\u015fa\u011f\u0131 y\u00f6nl\u00fc riski s\u0131n\u0131rlamak i\u00e7in mevcut fiyat seviyelerinin %10-15 alt\u0131nda koruyucu al\u0131m opsiyonlar\u0131 ile yaka stratejileri uygularlar.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Risk Fakt\u00f6r\u00fc<\/th>\n<th>Potansiyel Etki<\/th>\n<th>Azaltma Stratejisi<\/th>\n<th>Hisse Fiyat\u0131 \u00dczerindeki Tarihsel Etki<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Patent U\u00e7urumu<\/td>\n<td>Etkilenen \u00fcr\u00fcnler i\u00e7in potansiyel %15-20 gelir d\u00fc\u015f\u00fc\u015f\u00fc<\/td>\n<td>Boru hatt\u0131 geli\u015ftirme, ya\u015fam d\u00f6ng\u00fcs\u00fc y\u00f6netimi, stratejik sat\u0131n almalar<\/td>\n<td>Benzer tarihsel vakalarda -%8 ila -%12<\/td>\n<\/tr>\n<tr>\n<td>Fiyat Bask\u0131s\u0131<\/td>\n<td>\u00d6zellikle geli\u015fmi\u015f pazarlarda marj s\u0131k\u0131\u015fmas\u0131<\/td>\n<td>Co\u011frafi \u00e7e\u015fitlendirme, de\u011fer bazl\u0131 fiyatland\u0131rma modelleri<\/td>\n<td>D\u00fczenleyici duyurular\u0131n ard\u0131ndan -%3 ila -%5<\/td>\n<\/tr>\n<tr>\n<td>Ar-Ge Verimlili\u011fi<\/td>\n<td>Gelecekteki b\u00fcy\u00fcmeyi etkileyen daha y\u00fcksek maliyetler, daha d\u00fc\u015f\u00fck ba\u015far\u0131 oranlar\u0131<\/td>\n<td>D\u0131\u015f ortakl\u0131klar, AI destekli ke\u015fif, odaklanm\u0131\u015f terap\u00f6tik alanlar<\/td>\n<td>B\u00fcy\u00fck deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131nda -%5 ila -%15<\/td>\n<\/tr>\n<tr>\n<td>D\u00fczenleyici Ortam<\/td>\n<td>Onay gecikmeleri, ek \u00e7al\u0131\u015fma gereksinimleri<\/td>\n<td>Erken d\u00fczenleyici kat\u0131l\u0131m, sa\u011flam klinik deneme tasar\u0131mlar\u0131<\/td>\n<td>D\u00fczenleyici aksiliklerde -%4 ila -%7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>Yat\u0131r\u0131m Stratejileri: PFE Pozisyonlar\u0131na Yakla\u015f\u0131mlar<\/h2>\nFarkl\u0131 yat\u0131r\u0131mc\u0131lar, her biri belirli finansal hedefler ve risk toleranslar\u0131yla uyumlu olarak Pfizer hisse pozisyonlar\u0131na \u00e7e\u015fitli yakla\u015f\u0131mlar ba\u015far\u0131yla uygulam\u0131\u015flard\u0131r. PFE'nin portf\u00f6y\u00fcn\u00fcz i\u00e7in iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcrken, bu stratejik yakla\u015f\u0131mlar\u0131 incelemek de\u011ferli bir perspektif sunar.\n<h3>De\u011fer Tabanl\u0131 Birikim Stratejisi<\/h3>\n20 y\u0131ll\u0131k deneyime sahip bir portf\u00f6y y\u00f6neticisi olan Sarah K., Pocket Option analistleriyle Pfizer'a y\u00f6nelik de\u011fer tabanl\u0131 yakla\u015f\u0131m\u0131n\u0131 payla\u015ft\u0131: \"PFE i\u00e7in temett\u00fc getirisi %4,5'i a\u015ft\u0131\u011f\u0131nda ve F\/K oran\u0131 sekt\u00f6r ortalamalar\u0131n\u0131n alt\u0131na d\u00fc\u015ft\u00fc\u011f\u00fcnde sistematik bir sat\u0131n alma program\u0131 uygular\u0131z. Bu de\u011fer odakl\u0131 yakla\u015f\u0131m, be\u015f y\u0131ll\u0131k tutma d\u00f6nemlerinde s\u00fcrekli olarak alfa \u00fcretmi\u015ftir.\"\n\nEkibinin metodolojisi \u015funlar\u0131 i\u00e7erir:\n<ul>\n \t<li>De\u011ferleme metrikleri ilk al\u0131m sinyallerini tetikledi\u011finde (F\/K 13'\u00fcn alt\u0131nda, getiri %4,5'in \u00fczerinde) planlanan pozisyonun %25'ini tahsis etme<\/li>\n \t<li>Temel unsurlar de\u011fi\u015fmeden kal\u0131rsa, maliyet ortalamas\u0131 faydalar\u0131 elde etmek i\u00e7in %5 daha fazla fiyat d\u00fc\u015f\u00fc\u015f\u00fcnde %25 ekleme<\/li>\n \t<li>Boru hatt\u0131 geli\u015fmelerinin ve y\u00f6netim uygulamalar\u0131n\u0131n kapsaml\u0131 de\u011ferlendirilmesinden sonra pozisyonu tamamlama, genellikle 60-90 g\u00fcn i\u00e7inde<\/li>\n \t<li>Y\u0131ll\u0131k %2-3 getiri art\u0131rmak i\u00e7in daha y\u00fcksek volatilite d\u00f6nemlerinde kapal\u0131 al\u0131m stratejileri uygulama<\/li>\n<\/ul>\nBu disiplinli yakla\u015f\u0131m, m\u00fc\u015fterilerinin Pfizer'da avantajl\u0131 giri\u015f noktalar\u0131nda \u00f6nemli pozisyonlar olu\u015fturmalar\u0131na olanak tan\u0131m\u0131\u015f, mevcut piyasa fiyatlar\u0131n\u0131n %18 alt\u0131nda ortalama maliyet baz\u0131na ula\u015f\u0131rken, son d\u00f6rt y\u0131lda yat\u0131r\u0131lan her 100.000 $ i\u00e7in 13.750 $ temett\u00fc toplam\u0131\u015ft\u0131r. Sarah, Pfizer'\u0131n temett\u00fc getirisi tarihsel diren\u00e7 seviyelerinin \u00fczerine \u00e7\u0131kt\u0131\u011f\u0131nda optimal giri\u015f noktalar\u0131n\u0131 belirlemek i\u00e7in Pocket Option'\u0131n \u00e7ok zaman dilimli getiri tarama arac\u0131n\u0131 \u00f6zellikle kullan\u0131yor.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Yat\u0131r\u0131m Stratejisi<\/th>\n<th>En Uygun Olan<\/th>\n<th>Beklenen Sonu\u00e7<\/th>\n<th>Uygulama Yakla\u015f\u0131m\u0131<\/th>\n<th>Tarihsel Performans<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gelir Odakl\u0131<\/td>\n<td>Emekliler, gelir yat\u0131r\u0131mc\u0131lar\u0131<\/td>\n<td>%5+ sabit getiri ile orta derecede b\u00fcy\u00fcme<\/td>\n<td>Temett\u00fc yeniden yat\u0131r\u0131m\u0131 ile tam pozisyonlar<\/td>\n<td>%9,2 y\u0131ll\u0131k toplam getiri (2018-2024)<\/td>\n<\/tr>\n<tr>\n<td>De\u011fer Birikimi<\/td>\n<td>Sab\u0131rl\u0131 uzun vadeli yat\u0131r\u0131mc\u0131lar<\/td>\n<td>3-5 y\u0131l i\u00e7inde sermaye kazanc\u0131<\/td>\n<td>De\u011ferleme metriklerinde a\u015famal\u0131 al\u0131m<\/td>\n<td>%12,7 y\u0131ll\u0131k toplam getiri (2018-2024)<\/td>\n<\/tr>\n<tr>\n<td>Kataliz\u00f6r Ticareti<\/td>\n<td>Aktif yat\u0131r\u0131mc\u0131lar<\/td>\n<td>Pozitif haber olaylar\u0131nda %10-15 kazan\u00e7<\/td>\n<td>Veri yay\u0131nlar\u0131 etraf\u0131nda opsiyon stratejileri<\/td>\n<td>%18,3 i\u015flem ba\u015f\u0131na, %63 kazanma oran\u0131<\/td>\n<\/tr>\n<tr>\n<td>Sekt\u00f6r Da\u011f\u0131l\u0131m\u0131<\/td>\n<td>Dengeli portf\u00f6yler<\/td>\n<td>Defansif \u00f6zelliklere sahip sa\u011fl\u0131k sekt\u00f6r\u00fc maruziyeti<\/td>\n<td>Sekt\u00f6r a\u011f\u0131rl\u0131\u011f\u0131 olarak standart pozisyon<\/td>\n<td>%7,8 y\u0131ll\u0131k toplam getiri (2018-2024)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPocket Option platformlar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar, \u00f6zellikle b\u00fcy\u00fck klinik deneme sonu\u00e7lar\u0131 veya FDA kararlar\u0131 \u00f6ncesinde Pfizer etraf\u0131nda opsiyon tabanl\u0131 stratejiler uygularlar. Bu yakla\u015f\u0131mlar, fiyat hareketlerine kald\u0131ra\u00e7l\u0131 maruz kalma sa\u011flarken, do\u011frudan hisse sahipli\u011finden daha kesin risk parametreleri tan\u0131mlayabilir.\n<h2>K\u0131yaslama Analizi: PFE vs. \u0130la\u00e7 Sekt\u00f6r\u00fc E\u015fleri<\/h2>\nPFE'nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 belirlemek, yat\u0131r\u0131m faydalar\u0131n\u0131 e\u015f \u015firketlerle kar\u015f\u0131la\u015ft\u0131rarak ba\u011flamsalla\u015ft\u0131rmay\u0131 gerektirir. Bu kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u00e7er\u00e7eve, Pfizer'\u0131n ila\u00e7 manzaras\u0131ndaki g\u00f6receli g\u00fc\u00e7l\u00fc ve zay\u0131f y\u00f6nlerini vurgular.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Metrik<\/th>\n<th>Pfizer (PFE)<\/th>\n<th>Merck (MRK)<\/th>\n<th>Eli Lilly (LLY)<\/th>\n<th>Bristol Myers Squibb (BMY)<\/th>\n<th>End\u00fcstri Ortalamas\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u0130leriye D\u00f6n\u00fck F\/K Oran\u0131<\/td>\n<td>12,7<\/td>\n<td>14,9<\/td>\n<td>41,2<\/td>\n<td>8,6<\/td>\n<td>15,0<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Getirisi<\/td>\n<td>%5,4<\/td>\n<td>%2,6<\/td>\n<td>%0,8<\/td>\n<td>%4,8<\/td>\n<td>%2,6<\/td>\n<\/tr>\n<tr>\n<td>5 Y\u0131ll\u0131k Gelir Bile\u015fik B\u00fcy\u00fcme Oran\u0131<\/td>\n<td>%7,2<\/td>\n<td>%6,8<\/td>\n<td>%12,4<\/td>\n<td>%5,7<\/td>\n<td>%6,4<\/td>\n<\/tr>\n<tr>\n<td>Gelirin % Olarak Ar-Ge<\/td>\n<td>%21,3<\/td>\n<td>%25,6<\/td>\n<td>%29,1<\/td>\n<td>%24,2<\/td>\n<td>%22,8<\/td>\n<\/tr>\n<tr>\n<td>Bor\u00e7\/FAV\u00d6K<\/td>\n<td>2,8<\/td>\n<td>1,9<\/td>\n<td>1,2<\/td>\n<td>3,2<\/td>\n<td>2,3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nBu kar\u015f\u0131la\u015ft\u0131rma, Pfizer'\u0131n end\u00fcstri ortalamas\u0131na g\u00f6re %107 daha y\u00fcksek temett\u00fc getirisi sundu\u011funu (5,4% vs 2,6%) ve e\u015f ortalama F\/K oran\u0131na g\u00f6re %15 indirimle i\u015flem g\u00f6rd\u00fc\u011f\u00fcn\u00fc (12,7 vs 15,0) ortaya koyuyor. Pocket Option'\u0131n sekt\u00f6r kar\u015f\u0131la\u015ft\u0131rma arac\u0131, PFE'nin \u00e7ekici g\u00f6receli de\u011fer metriklerini vurguluyor ve onu temett\u00fc getirisi i\u00e7in en \u00fcst \u00e7eyrekte ve de\u011ferleme \u00e7arpanlar\u0131 i\u00e7in en alt \u00e7eyrekte konumland\u0131r\u0131yor - genellikle d\u00fc\u015f\u00fck de\u011ferli menkul k\u0131ymetlerle ili\u015fkilendirilen nadir bir kombinasyon.\n[cta_button text=\"Start Trading\"]\n<h2>Sonu\u00e7: Pfizer \u0130\u00e7in Yat\u0131r\u0131m Vakas\u0131n\u0131n Sentezi<\/h2>\n\"PFE iyi bir hisse senedi mi?\" sorusu nihayetinde bireysel yat\u0131r\u0131m hedeflerine, zaman ufkuna ve portf\u00f6y ba\u011flam\u0131na ba\u011fl\u0131d\u0131r. Ancak, bu kapsaml\u0131 analizden birka\u00e7 net g\u00f6zlem ortaya \u00e7\u0131k\u0131yor:\n\nPfizer, S&P 500 hisselerinin %93'\u00fcnden daha y\u00fcksek olan %5,4 temett\u00fc getirisi ile cazip bir de\u011fer \u00f6nerisi sunuyor. Mevcut de\u011ferleme metrikleri, 5 y\u0131ll\u0131k tarihsel F\/K ortalamalar\u0131na g\u00f6re %12 d\u00fc\u015f\u00fck de\u011ferleme ve ila\u00e7 sekt\u00f6r\u00fc \u00e7arpanlar\u0131na g\u00f6re %18 indirim \u00f6neriyor, bu da potansiyel bir g\u00fcvenlik marj\u0131 sa\u011fl\u0131yor. \u015eirketin sa\u011flam boru hatt\u0131 ve stratejik sat\u0131n alma yakla\u015f\u0131m\u0131, olgun \u00fcr\u00fcn portf\u00f6y\u00fcn\u00fcn \u00f6tesinde potansiyel b\u00fcy\u00fcme i\u00e7in konumland\u0131r\u0131yor.\n\nPocket Option'\u0131n kapsaml\u0131 ila\u00e7 sekt\u00f6r\u00fc ara\u00e7 setini kullanan yat\u0131r\u0131mc\u0131lar i\u00e7in Pfizer, \u00f6l\u00e7\u00fclebilir metriklerle nesnel olarak dengeli bir se\u00e7enek sunuyor: \u00fcst \u00e7eyrek temett\u00fc getirisi (%5,4), alt \u00e7eyrek F\/K oran\u0131 (12,7) ve 2030'a kadar %14,2 Bile\u015fik B\u00fcy\u00fcme Oran\u0131 ile b\u00fcy\u00fcmesi \u00f6ng\u00f6r\u00fclen onkoloji pazarlar\u0131nda stratejik boru hatt\u0131 konumland\u0131rmas\u0131. \u015eirketin finansal g\u00fcc\u00fc, hem devam eden temett\u00fc \u00f6demelerini hem de gelecekteki geli\u015fim i\u00e7in stratejik esnekli\u011fi destekliyor. Fiyat bask\u0131s\u0131 ve patent s\u00fcrelerinin dolmas\u0131 gibi sekt\u00f6r genelindeki zorluklarla kar\u015f\u0131 kar\u015f\u0131ya kalmas\u0131na ra\u011fmen, Pfizer'\u0131n \u00f6l\u00e7e\u011fi ve \u00e7e\u015fitlili\u011fi anlaml\u0131 rekabet avantajlar\u0131 sa\u011fl\u0131yor.\n\nPfizer'\u0131 sadece bir al\u0131m veya ka\u00e7\u0131n\u0131lmas\u0131 gereken bir hisse olarak g\u00f6rmek yerine, sofistike yat\u0131r\u0131mc\u0131lar, de\u011ferleme, teknik sinyaller ve boru hatt\u0131 kataliz\u00f6rlerine dayal\u0131 olarak maruz kalmay\u0131 optimize etmek i\u00e7in a\u015famal\u0131 giri\u015f stratejileri veya opsiyon tabanl\u0131 yakla\u015f\u0131mlar uygulamay\u0131 d\u00fc\u015f\u00fcnebilirler. Gelir \u00f6zelliklerine sahip ila\u00e7 sekt\u00f6r\u00fc maruziyeti arayan yat\u0131r\u0131mc\u0131lar i\u00e7in, PFE, Pocket Option'\u0131n \u00e7ok zaman dilimli analiz ara\u00e7lar\u0131nda g\u00f6r\u00fcnen teknik destek seviyelerinde a\u015famal\u0131 giri\u015flerle, %3-5 portf\u00f6y tahsisi i\u00e7in bir \u00e7ekirdek sa\u011fl\u0131k sekt\u00f6r\u00fc holdingi olarak de\u011ferlendirmeye de\u011fer.\n\n<\/div>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<div class=\"custom-html-container\">\n<h2>\u0130la\u00e7 Yat\u0131r\u0131mlar\u0131n\u0131n Geli\u015fen Manzaras\u0131<\/h2>\n<p>\u0130la\u00e7 sekt\u00f6r\u00fc, tarihsel olarak yat\u0131r\u0131mc\u0131lara savunma \u00f6zellikleri ve b\u00fcy\u00fcme potansiyelinin benzersiz bir kombinasyonunu sunmu\u015ftur. Bu rekabet\u00e7i ortamda, Pfizer Inc. (NYSE: PFE), gelir a\u00e7\u0131s\u0131ndan k\u00fcresel olarak 4. en b\u00fcy\u00fck ila\u00e7 \u015firketi olarak duruyor ve piyasa de\u011feri 200 milyar dolar\u0131 a\u015f\u0131yor. Yat\u0131r\u0131mc\u0131lar s\u0131k s\u0131k sorar: PFE, bug\u00fcn\u00fcn piyasa ortam\u0131nda iyi bir hisse senedi mi? Bu soru, be\u015f \u00f6zel boyutun incelenmesini gerektirir: gelir \u00e7e\u015fitlili\u011fi (2023&#8217;te 58,5 milyar dolar), boru hatt\u0131 potansiyeli (43 Faz 3 aday\u0131), temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fi (14 y\u0131l \u00fcst \u00fcste b\u00fcy\u00fcme), de\u011ferleme metrikleri (F\/K oran\u0131 12,7) ve Pocket Option&#8217;\u0131n analitik platformundaki teknik g\u00f6stergeler.<\/p>\n<p>Pocket Option gibi platformlardaki yat\u0131r\u0131mc\u0131lar ila\u00e7 hisselerini analiz ederken, birka\u00e7 kritik fakt\u00f6r\u00fc dikkate al\u0131rlar: gelir ak\u0131\u015flar\u0131, boru hatt\u0131 potansiyeli, temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fi ve de\u011ferleme metrikleri. 1849&#8217;da Charles Pfizer&#8217;\u0131n \u00f6nc\u00fc anti-parazitik ilac\u0131yla ba\u015flayan 173 y\u0131ll\u0131k miras\u0131yla Pfizer, hem savunma hem de b\u00fcy\u00fcme odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6zellikle ilgin\u00e7 bir vaka \u00e7al\u0131\u015fmas\u0131 sunuyor.<\/p>\n<h2>Pfizer&#8217;\u0131n Finansal Sa\u011fl\u0131\u011f\u0131: Say\u0131lara Derinlemesine Bak\u0131\u015f<\/h2>\n<p>Pfizer hissesinin al\u0131n\u0131p al\u0131nmayaca\u011f\u0131na karar vermeden \u00f6nce, finansal temellerini incelemek \u00f6nemli bir ba\u011flam sa\u011flar. \u015eirket, 2020&#8217;de 41,9 milyar dolardan 2022&#8217;de 81,3 milyar dolara rekor k\u0131ran gelir art\u0131\u015f\u0131 g\u00f6sterdi, ard\u0131ndan pandemiyle ilgili \u00fcr\u00fcnlerinin benzeri g\u00f6r\u00fclmemi\u015f nakit ak\u0131\u015f\u0131 yaratmas\u0131n\u0131n ard\u0131ndan 2023&#8217;te 58,5 milyar dolara normalle\u015fti.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Finansal Metrik<\/th>\n<th>2023 De\u011feri<\/th>\n<th>2024 Projeksiyonu<\/th>\n<th>5 Y\u0131ll\u0131k E\u011filim<\/th>\n<th>Sekt\u00f6r Ortalamas\u0131na G\u00f6re<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gelir<\/td>\n<td>58,5 milyar dolar<\/td>\n<td>61,4 milyar dolar<\/td>\n<td>COVID sonras\u0131 zirve sonras\u0131 istikrar<\/td>\n<td>+%7,3<\/td>\n<\/tr>\n<tr>\n<td>Net Gelir<\/td>\n<td>10,2 milyar dolar<\/td>\n<td>11,7 milyar dolar<\/td>\n<td>Orta derecede art\u0131\u015f<\/td>\n<td>+%4,8<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Verimi<\/td>\n<td>%5,4<\/td>\n<td>%5,6 (tahmini)<\/td>\n<td>S\u00fcrekli art\u0131\u015f<\/td>\n<td>+%2,6<\/td>\n<\/tr>\n<tr>\n<td>F\/K Oran\u0131<\/td>\n<td>13,2<\/td>\n<td>12,7 (projeksiyon)<\/td>\n<td>Sekt\u00f6r ortalamas\u0131n\u0131n alt\u0131nda<\/td>\n<td>-%15,3<\/td>\n<\/tr>\n<tr>\n<td>Serbest Nakit Ak\u0131\u015f\u0131<\/td>\n<td>18,3 milyar dolar<\/td>\n<td>19,7 milyar dolar<\/td>\n<td>G\u00fc\u00e7l\u00fc ve s\u00fcrd\u00fcr\u00fclebilir<\/td>\n<td>+%12,5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu finansal g\u00f6stergeler, gelecekteki b\u00fcy\u00fcmeyi art\u0131rabilecek stratejik giri\u015fimlere olanak tan\u0131yan \u00f6nemli nakit rezervlerine sahip bir \u015firketi ortaya koyuyor. Pocket Option&#8217;\u0131n \u00f6zelle\u015ftirilebilir hisse senedi tarama ara\u00e7lar\u0131, PFE&#8217;nin ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131na g\u00f6re %27 fiyat-kazan\u00e7 indirimi sundu\u011funu vurguluyor ve bu da y\u0131ll\u0131k 18,3 milyar dolarl\u0131k nakit \u00fcretme yetenekleri g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6nemli bir d\u00fc\u015f\u00fck de\u011ferleme oldu\u011funu g\u00f6steriyor.<\/p>\n<h3>Temett\u00fc Avantaj\u0131: Gelir \u00dcretme Potansiyeli<\/h3>\n<p>Bir\u00e7ok yat\u0131r\u0131mc\u0131n\u0131n PFE hissesinin al\u0131n\u0131p al\u0131nmayaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcrken Pfizer&#8217;\u0131 dikkate almas\u0131n\u0131n cazip bir nedeni, S&#038;P 500 hisselerinin %3&#8217;\u00fc aras\u0131nda yer alan temett\u00fc profiliyle ilgilidir. Mevcut fiyat seviyelerinde %5&#8217;i a\u015fan bir getiri ile Pfizer, ila\u00e7 end\u00fcstrisinin en c\u00f6mert temett\u00fc \u00f6deyenleri aras\u0131nda yer al\u0131yor.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Temett\u00fc Aspekti<\/th>\n<th>Pfizer Performans\u0131<\/th>\n<th>End\u00fcstri Ortalamas\u0131<\/th>\n<th>Avantaj<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mevcut Getiri<\/td>\n<td>%5,4<\/td>\n<td>%2,8<\/td>\n<td>+%2,6<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc B\u00fcy\u00fcme Oran\u0131 (5 y\u0131l)<\/td>\n<td>Y\u0131ll\u0131k %3,7<\/td>\n<td>Y\u0131ll\u0131k %2,9<\/td>\n<td>+%0,8<\/td>\n<\/tr>\n<tr>\n<td>\u00d6deme Oran\u0131<\/td>\n<td>%65<\/td>\n<td>%52<\/td>\n<td>+%13<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Tutarl\u0131l\u0131\u011f\u0131<\/td>\n<td>14 y\u0131l \u00fcst \u00fcste art\u0131\u015f<\/td>\n<td>8,3 y\u0131l ortalama<\/td>\n<td>+5,7 y\u0131l<\/td>\n<\/tr>\n<tr>\n<td>10.000 $ Ba\u015f\u0131na Y\u0131ll\u0131k Gelir<\/td>\n<td>540 $<\/td>\n<td>280 $<\/td>\n<td>+260 $<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu temett\u00fc profili, \u00f6zellikle piyasa dalgalanmalar\u0131 d\u00f6nemlerinde gelir odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in Pfizer&#8217;\u0131 \u00f6zellikle \u00e7ekici k\u0131l\u0131yor. Pocket Option&#8217;daki teknik analistler, bu tutarl\u0131 gelir ak\u0131\u015f\u0131n\u0131, Pocket Option&#8217;\u0131n getiri analizi ara\u00e7lar\u0131 taraf\u0131ndan belirlenen %6,2&#8217;lik tarihsel getiri tavanlar\u0131na dayal\u0131 olarak yakla\u015f\u0131k 30 $&#8217;da teorik bir destek seviyesi olu\u015fturdu\u011funu s\u0131k s\u0131k vurgularlar.<\/p>\n<h2>Boru Hatt\u0131 Potansiyeli: Gelecekteki Gelir Kataliz\u00f6rleri<\/h2>\n<p>Pfizer hissesinin al\u0131n\u0131p al\u0131nmayaca\u011f\u0131n\u0131 incelerken, sofistike yat\u0131r\u0131mc\u0131lar mevcut finansallar\u0131n \u00f6tesine bakarak gelecekteki b\u00fcy\u00fcme s\u00fcr\u00fcc\u00fclerini de\u011ferlendirirler. Pfizer&#8217;\u0131n ara\u015ft\u0131rma ve geli\u015ftirme boru hatt\u0131, gelecekteki geliri \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilecek onkoloji, imm\u00fcnoloji ve nadir hastal\u0131klar alanlar\u0131nda 26 ge\u00e7 a\u015fama (Faz 2\/3) aday\u0131 i\u00e7ermektedir.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Terap\u00f6tik Alan<\/th>\n<th>Dikkate De\u011fer Boru Hatt\u0131 Adaylar\u0131<\/th>\n<th>Potansiyel Pazar B\u00fcy\u00fckl\u00fc\u011f\u00fc<\/th>\n<th>Geli\u015ftirme A\u015famas\u0131<\/th>\n<th>Beklenen Gelir Etkisi (Y\u0131ll\u0131k)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Onkoloji<\/td>\n<td>Elranatamab, Sasanlimab<\/td>\n<td>2027&#8217;ye kadar 280 milyar dolar<\/td>\n<td>Faz 3, Faz 2<\/td>\n<td>3,8-4,5 milyar dolar<\/td>\n<\/tr>\n<tr>\n<td>\u0130mm\u00fcnoloji<\/td>\n<td>Ritlecitinib, Brepocitinib<\/td>\n<td>2027&#8217;ye kadar 150 milyar dolar<\/td>\n<td>Faz 3, Faz 2<\/td>\n<td>2,1-2,7 milyar dolar<\/td>\n<\/tr>\n<tr>\n<td>Nadir Hastal\u0131klar<\/td>\n<td>Fordadistrogene movaparvovec<\/td>\n<td>2026&#8217;ya kadar 180 milyar dolar<\/td>\n<td>Faz 3<\/td>\n<td>1,5-1,9 milyar dolar<\/td>\n<\/tr>\n<tr>\n<td>A\u015f\u0131lar<\/td>\n<td>RSV a\u015f\u0131s\u0131, Lyme hastal\u0131\u011f\u0131 a\u015f\u0131s\u0131<\/td>\n<td>2028&#8217;e kadar 120 milyar dolar<\/td>\n<td>Faz 3, Faz 2<\/td>\n<td>2,3-3,1 milyar dolar<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu sa\u011flam boru hatt\u0131, PFE&#8217;nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131 sorusunu merak edenler i\u00e7in \u00f6nemli bir soruyu do\u011frudan ele al\u0131yor &#8211; \u015firketin mevcut \u00fcr\u00fcnlerinin \u00f6tesinde gelecekteki b\u00fcy\u00fcme potansiyeli. Pfizer&#8217;\u0131n 2023&#8217;te 11,8 milyar dolarl\u0131k (gelirin %20,2&#8217;si) \u00f6nemli Ar-Ge yat\u0131r\u0131m\u0131, bu boru hatt\u0131n\u0131 besliyor ve analist konsens\u00fcs\u00fcne g\u00f6re 2028&#8217;e kadar 280 milyar dolarl\u0131k onkoloji pazar\u0131nda %15-20 pazar pay\u0131 yakalama potansiyeline sahip.<\/p>\n<h3>Stratejik Sat\u0131n Almalar ve Entegrasyon Ba\u015far\u0131s\u0131<\/h3>\n<p>Dahili geli\u015fimin \u00f6tesinde, Pfizer, pazar varl\u0131\u011f\u0131n\u0131 geni\u015fleten stratejik sat\u0131n almalarda beceri g\u00f6stermi\u015ftir. Son sat\u0131n almalar \u015funlar\u0131 i\u00e7erir:<\/p>\n<ul>\n<li>Seagen (2023, 43 milyar dolar) \u2013 Antikor-ila\u00e7 konjugat teknolojileriyle onkoloji portf\u00f6y\u00fcn\u00fc geni\u015fletme; 2024&#8217;\u00fcn ilk \u00e7eyre\u011finde 650 milyon dolar gelir sa\u011flad\u0131, beklentilerin %12 \u00fczerinde<\/li>\n<li>Arena Pharmaceuticals (2022, 6,7 milyar dolar) \u2013 \u0130mm\u00fcnoloji ve inflamasyon boru hatt\u0131n\u0131 g\u00fc\u00e7lendirme; etrasimod onay\u0131 Mart 2024&#8217;te, tahmini zirve sat\u0131\u015flar\u0131 3,1 milyar dolar<\/li>\n<li>Trillium Therapeutics (2021, 2,3 milyar dolar) \u2013 Onkoloji yeteneklerini g\u00fc\u00e7lendirme; TTI-622, tedavisi zor kan kanserlerinde %37 yan\u0131t oran\u0131 g\u00f6steriyor<\/li>\n<li>ReViral (2022, 525 milyon dolar) \u2013 Solunum sinsityal vir\u00fcs\u00fc (RSV) terap\u00f6tiklerini ekleme; Faz 2 denemeleri, plaseboya kar\u015f\u0131 %86 viral y\u00fck azalt\u0131m\u0131 g\u00f6steriyor<\/li>\n<\/ul>\n<p>Bu sat\u0131n almalar, Pfizer&#8217;\u0131n organik b\u00fcy\u00fcmeyi yenilik\u00e7i teknolojilerin ve boru hatt\u0131 varl\u0131klar\u0131n\u0131n hedefli sat\u0131n al\u0131mlar\u0131yla destekleme stratejisini yans\u0131t\u0131yor. Pocket Option&#8217;\u0131n analitik ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar i\u00e7in bu stratejik hamleler, \u00f6nceki sat\u0131n almalarda %13,7 y\u0131ll\u0131k ortalama ROI ile g\u00f6sterilebilir g\u00fcven sa\u011flar.<\/p>\n<h2>Yat\u0131r\u0131mc\u0131 Ba\u015far\u0131 Hikayeleri: Ger\u00e7ek D\u00fcnya PFE Yat\u0131r\u0131m Sonu\u00e7lar\u0131<\/h2>\n<p>Teorik yat\u0131r\u0131m faydalar\u0131n\u0131 anlamak de\u011ferlidir, ancak ger\u00e7ek d\u00fcnya yat\u0131r\u0131mc\u0131 deneyimlerini incelemek, PFE&#8217;nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 belirlerken pratik bir ba\u011flam sa\u011flar. A\u015fa\u011f\u0131daki vakalar, farkl\u0131 yat\u0131r\u0131m yakla\u015f\u0131mlar\u0131n\u0131 ve sonu\u00e7lar\u0131n\u0131 g\u00f6stermektedir.<\/p>\n<h3>Vaka \u00c7al\u0131\u015fmas\u0131: Temett\u00fc Yeniden Yat\u0131r\u0131m Stratejisi<\/h3>\n<p>58 ya\u015f\u0131ndaki emekli m\u00fchendis Michael T., 2011 y\u0131l\u0131nda Pfizer hissesi ile bir temett\u00fc yeniden yat\u0131r\u0131m plan\u0131 (DRIP) uygulad\u0131. \u0130lk yat\u0131r\u0131m\u0131 olan 75.000 dolar, hisse ba\u015f\u0131na ortalama 19,23 dolardan yakla\u015f\u0131k 3.900 hisse sat\u0131n ald\u0131.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Y\u0131l<\/th>\n<th>Sahip Olunan Hisseler<\/th>\n<th>Al\u0131nan Y\u0131ll\u0131k Temett\u00fcler<\/th>\n<th>Toplam Yat\u0131r\u0131m De\u011feri<\/th>\n<th>K\u00fcm\u00fclatif Temett\u00fcler<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2011<\/td>\n<td>3,900<\/td>\n<td>3,042 $<\/td>\n<td>75,000 $<\/td>\n<td>3,042 $<\/td>\n<\/tr>\n<tr>\n<td>2015<\/td>\n<td>4,523<\/td>\n<td>5,066 $<\/td>\n<td>146,545 $<\/td>\n<td>17,358 $<\/td>\n<\/tr>\n<tr>\n<td>2020<\/td>\n<td>5,687<\/td>\n<td>8,644 $<\/td>\n<td>209,187 $<\/td>\n<td>34,772 $<\/td>\n<\/tr>\n<tr>\n<td>2024<\/td>\n<td>6,752<\/td>\n<td>12,153 $<\/td>\n<td>236,320 $<\/td>\n<td>55,947 $<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&#8220;Temett\u00fc art\u0131\u015flar\u0131 ve yeniden yat\u0131r\u0131m\u0131n birle\u015fimi, hem gelir ak\u0131\u015f\u0131m\u0131 hem de toplam pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcm\u00fc \u00f6nemli \u00f6l\u00e7\u00fcde b\u00fcy\u00fcten bir bile\u015fik etki yaratt\u0131,&#8221; diye a\u00e7\u0131klad\u0131 Michael, Pocket Option analistlerine bir yat\u0131r\u0131mc\u0131 yuvarlak masas\u0131nda. &#8220;Pfizer&#8217;\u0131n hisse fiyat\u0131 dalgalanma ya\u015farken, b\u00fcy\u00fcyen temett\u00fc, piyasa ko\u015fullar\u0131ndan ba\u011f\u0131ms\u0131z olarak tutarl\u0131 getiriler sa\u011flad\u0131 ve 13 y\u0131l boyunca toplam 42,905 $ temett\u00fc geliri elde etmeme ve hisse say\u0131m\u0131 \u00fc\u00e7 kat\u0131na \u00e7\u0131karmama olanak tan\u0131d\u0131.&#8221;<\/p>\n<p>Bu vaka, Pfizer&#8217;\u0131n temett\u00fc politikas\u0131n\u0131n, \u00f6zellikle daha uzun zaman dilimlerine sahip yat\u0131r\u0131mc\u0131lar i\u00e7in, fiyat zay\u0131fl\u0131\u011f\u0131 d\u00f6nemlerinde temett\u00fcleri yeniden yat\u0131ranlar i\u00e7in zamanla \u00f6nemli bir servet yaratabilece\u011fini g\u00f6stermektedir. Michael, piyasa d\u00fc\u015f\u00fc\u015fleri s\u0131ras\u0131nda pozisyon boyutland\u0131rmas\u0131n\u0131 optimize etmek i\u00e7in Pocket Option&#8217;\u0131n temett\u00fc yeniden yat\u0131r\u0131m hesaplay\u0131c\u0131s\u0131n\u0131 kullan\u0131yor.<\/p>\n<h2>Teknik Analiz Perspektifleri: PFE Hissesi \u0130\u00e7in Giri\u015f Noktalar\u0131<\/h2>\n<p>Pocket Option&#8217;\u0131n teknik analiz ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar i\u00e7in Pfizer hissesi i\u00e7in en uygun giri\u015f noktalar\u0131n\u0131 belirlemek, PFE hisse hareketleri i\u00e7in istatistiksel \u00f6neme sahip \u00fc\u00e7 \u00f6zel teknik deseni incelemeyi gerektirir: \u00e7ift dipler, alt\u0131n kesi\u015fimler ve pozitif RSI sapmas\u0131. Tarihsel analiz, bu desenlerin PFE i\u00e7in \u00f6nemli fiyat hareketlerinden \u00f6nce geldi\u011fini ortaya koyuyor.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Teknik Desen<\/th>\n<th>Tarihsel Olu\u015fum<\/th>\n<th>Tipik Sonu\u00e7<\/th>\n<th>Mevcut Durum<\/th>\n<th>Ba\u015far\u0131 Oran\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u00c7ift Dip<\/td>\n<td>Son on y\u0131lda 4 kez<\/td>\n<td>6 ay i\u00e7inde ortalama %17 yukar\u0131 y\u00f6nl\u00fc<\/td>\n<td>Olu\u015fuyor (12 Mart 2025)<\/td>\n<td>%75<\/td>\n<\/tr>\n<tr>\n<td>Alt\u0131n Kesi\u015fim (50 g\u00fcnl\u00fck MA, 200 g\u00fcnl\u00fck MA&#8217;n\u0131n \u00fczerine \u00e7\u0131k\u0131yor)<\/td>\n<td>2014&#8217;ten bu yana 6 kez<\/td>\n<td>Takip eden \u00e7eyrekte ortalama %12 kazan\u00e7<\/td>\n<td>Yakla\u015f\u0131yor (Tahmini 28 Nisan 2025)<\/td>\n<td>%83<\/td>\n<\/tr>\n<tr>\n<td>RSI Sapmas\u0131 (pozitif)<\/td>\n<td>2015&#8217;ten bu yana 9 kez<\/td>\n<td>45 g\u00fcn i\u00e7inde ortalama %8 yukar\u0131 y\u00f6nl\u00fc<\/td>\n<td>Mevcut (22 \u015eubat 2025&#8217;ten beri)<\/td>\n<td>%67<\/td>\n<\/tr>\n<tr>\n<td>Hacim Birikimi<\/td>\n<td>B\u00fcy\u00fck rallilerden \u00f6nce tutarl\u0131 desen<\/td>\n<td>S\u00fcrekli yukar\u0131 trendleri \u00f6ng\u00f6r\u00fcr<\/td>\n<td>Erken a\u015fama (14 g\u00fcn tamamland\u0131)<\/td>\n<td>%71<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Pocket Option platformlar\u0131ndaki teknik yat\u0131r\u0131mc\u0131lar, bu desenleri PFE pozisyonlar\u0131 i\u00e7in giri\u015f zamanlamas\u0131nda potansiyel olarak faydal\u0131 g\u00f6stergeler olarak tan\u0131mlam\u0131\u015flard\u0131r. Pocket Option&#8217;\u0131n teknik kontrol panelindeki tarihsel desen analizi, mevcut olu\u015fan \u00e7ift dip deseninin %73 olas\u0131l\u0131kla 120 g\u00fcn i\u00e7inde %12-17 fiyat art\u0131\u015f\u0131 ile sonu\u00e7lanaca\u011f\u0131n\u0131 g\u00f6stermektedir. Ancak, teknik analizin, Pfizer hissesinin sizin \u00f6zel yat\u0131r\u0131m stratejiniz i\u00e7in bir al\u0131m olup olmad\u0131\u011f\u0131n\u0131 de\u011ferlendirirken temel analizi tamamlamas\u0131 gerekti\u011fini vurgularlar.<\/p>\n<h2>Risk De\u011ferlendirmesi: Pfizer&#8217;\u0131n Kar\u015f\u0131la\u015ft\u0131\u011f\u0131 Zorluklar<\/h2>\n<p>Dikkatli yat\u0131r\u0131m analizi, f\u0131rsatlarla birlikte potansiyel riskleri de incelemeyi gerektirir. Pfizer&#8217;\u0131n performans\u0131n\u0131 etkileyebilecek ve PFE&#8217;nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 de\u011ferlendirirken dikkate al\u0131nmas\u0131 gereken birka\u00e7 zorluk vard\u0131r:<\/p>\n<ul>\n<li>Anahtar \u00fcr\u00fcnlerdeki patent s\u00fcrelerinin dolmas\u0131, gelir u\u00e7urumlar\u0131 yarat\u0131yor &#8211; en y\u00fcksek etki Eliquis \u00fczerinde (2026, y\u0131ll\u0131k 4,8 milyar dolar gelir riski)<\/li>\n<li>K\u00fcresel olarak h\u00fck\u00fcmetlerden ve \u00f6deme yapanlardan artan fiyat bask\u0131s\u0131 &#8211; y\u0131ll\u0131k %3-5 fiyat bask\u0131s\u0131 tahmini<\/li>\n<li>Boru hatt\u0131 ilerlemesini etkileyen klinik deneme aksilikleri &#8211; tarihsel olarak Faz 3 adaylar\u0131n\u0131n %27&#8217;sini etkiliyor<\/li>\n<li>Son sat\u0131n almalardan kaynaklanan entegrasyon zorluklar\u0131 &#8211; Seagen, tam sinerji ger\u00e7ekle\u015ftirmesi i\u00e7in 24-36 ay gerektiriyor<\/li>\n<li>\u0130la\u00e7 geli\u015ftirmeye \u00f6zg\u00fc dava riskleri &#8211; \u015fu anda potansiyel 1,2 milyar dolar maruz kalma ile 3 \u00f6nemli dava<\/li>\n<\/ul>\n<p>Bu risk fakt\u00f6rleri, Pfizer&#8217;\u0131n hisse fiyat\u0131n\u0131 periyodik olarak etkileyerek hem zorluklar hem de f\u0131rsatlar yaratmaktad\u0131r. Pocket Option&#8217;\u0131n risk y\u00f6netimi ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar, genellikle boru hatt\u0131 duyurular\u0131 s\u0131ras\u0131nda a\u015fa\u011f\u0131 y\u00f6nl\u00fc riski s\u0131n\u0131rlamak i\u00e7in mevcut fiyat seviyelerinin %10-15 alt\u0131nda koruyucu al\u0131m opsiyonlar\u0131 ile yaka stratejileri uygularlar.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Risk Fakt\u00f6r\u00fc<\/th>\n<th>Potansiyel Etki<\/th>\n<th>Azaltma Stratejisi<\/th>\n<th>Hisse Fiyat\u0131 \u00dczerindeki Tarihsel Etki<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Patent U\u00e7urumu<\/td>\n<td>Etkilenen \u00fcr\u00fcnler i\u00e7in potansiyel %15-20 gelir d\u00fc\u015f\u00fc\u015f\u00fc<\/td>\n<td>Boru hatt\u0131 geli\u015ftirme, ya\u015fam d\u00f6ng\u00fcs\u00fc y\u00f6netimi, stratejik sat\u0131n almalar<\/td>\n<td>Benzer tarihsel vakalarda -%8 ila -%12<\/td>\n<\/tr>\n<tr>\n<td>Fiyat Bask\u0131s\u0131<\/td>\n<td>\u00d6zellikle geli\u015fmi\u015f pazarlarda marj s\u0131k\u0131\u015fmas\u0131<\/td>\n<td>Co\u011frafi \u00e7e\u015fitlendirme, de\u011fer bazl\u0131 fiyatland\u0131rma modelleri<\/td>\n<td>D\u00fczenleyici duyurular\u0131n ard\u0131ndan -%3 ila -%5<\/td>\n<\/tr>\n<tr>\n<td>Ar-Ge Verimlili\u011fi<\/td>\n<td>Gelecekteki b\u00fcy\u00fcmeyi etkileyen daha y\u00fcksek maliyetler, daha d\u00fc\u015f\u00fck ba\u015far\u0131 oranlar\u0131<\/td>\n<td>D\u0131\u015f ortakl\u0131klar, AI destekli ke\u015fif, odaklanm\u0131\u015f terap\u00f6tik alanlar<\/td>\n<td>B\u00fcy\u00fck deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131nda -%5 ila -%15<\/td>\n<\/tr>\n<tr>\n<td>D\u00fczenleyici Ortam<\/td>\n<td>Onay gecikmeleri, ek \u00e7al\u0131\u015fma gereksinimleri<\/td>\n<td>Erken d\u00fczenleyici kat\u0131l\u0131m, sa\u011flam klinik deneme tasar\u0131mlar\u0131<\/td>\n<td>D\u00fczenleyici aksiliklerde -%4 ila -%7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>Yat\u0131r\u0131m Stratejileri: PFE Pozisyonlar\u0131na Yakla\u015f\u0131mlar<\/h2>\n<p>Farkl\u0131 yat\u0131r\u0131mc\u0131lar, her biri belirli finansal hedefler ve risk toleranslar\u0131yla uyumlu olarak Pfizer hisse pozisyonlar\u0131na \u00e7e\u015fitli yakla\u015f\u0131mlar ba\u015far\u0131yla uygulam\u0131\u015flard\u0131r. PFE&#8217;nin portf\u00f6y\u00fcn\u00fcz i\u00e7in iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcrken, bu stratejik yakla\u015f\u0131mlar\u0131 incelemek de\u011ferli bir perspektif sunar.<\/p>\n<h3>De\u011fer Tabanl\u0131 Birikim Stratejisi<\/h3>\n<p>20 y\u0131ll\u0131k deneyime sahip bir portf\u00f6y y\u00f6neticisi olan Sarah K., Pocket Option analistleriyle Pfizer&#8217;a y\u00f6nelik de\u011fer tabanl\u0131 yakla\u015f\u0131m\u0131n\u0131 payla\u015ft\u0131: &#8220;PFE i\u00e7in temett\u00fc getirisi %4,5&#8217;i a\u015ft\u0131\u011f\u0131nda ve F\/K oran\u0131 sekt\u00f6r ortalamalar\u0131n\u0131n alt\u0131na d\u00fc\u015ft\u00fc\u011f\u00fcnde sistematik bir sat\u0131n alma program\u0131 uygular\u0131z. Bu de\u011fer odakl\u0131 yakla\u015f\u0131m, be\u015f y\u0131ll\u0131k tutma d\u00f6nemlerinde s\u00fcrekli olarak alfa \u00fcretmi\u015ftir.&#8221;<\/p>\n<p>Ekibinin metodolojisi \u015funlar\u0131 i\u00e7erir:<\/p>\n<ul>\n<li>De\u011ferleme metrikleri ilk al\u0131m sinyallerini tetikledi\u011finde (F\/K 13&#8217;\u00fcn alt\u0131nda, getiri %4,5&#8217;in \u00fczerinde) planlanan pozisyonun %25&#8217;ini tahsis etme<\/li>\n<li>Temel unsurlar de\u011fi\u015fmeden kal\u0131rsa, maliyet ortalamas\u0131 faydalar\u0131 elde etmek i\u00e7in %5 daha fazla fiyat d\u00fc\u015f\u00fc\u015f\u00fcnde %25 ekleme<\/li>\n<li>Boru hatt\u0131 geli\u015fmelerinin ve y\u00f6netim uygulamalar\u0131n\u0131n kapsaml\u0131 de\u011ferlendirilmesinden sonra pozisyonu tamamlama, genellikle 60-90 g\u00fcn i\u00e7inde<\/li>\n<li>Y\u0131ll\u0131k %2-3 getiri art\u0131rmak i\u00e7in daha y\u00fcksek volatilite d\u00f6nemlerinde kapal\u0131 al\u0131m stratejileri uygulama<\/li>\n<\/ul>\n<p>Bu disiplinli yakla\u015f\u0131m, m\u00fc\u015fterilerinin Pfizer&#8217;da avantajl\u0131 giri\u015f noktalar\u0131nda \u00f6nemli pozisyonlar olu\u015fturmalar\u0131na olanak tan\u0131m\u0131\u015f, mevcut piyasa fiyatlar\u0131n\u0131n %18 alt\u0131nda ortalama maliyet baz\u0131na ula\u015f\u0131rken, son d\u00f6rt y\u0131lda yat\u0131r\u0131lan her 100.000 $ i\u00e7in 13.750 $ temett\u00fc toplam\u0131\u015ft\u0131r. Sarah, Pfizer&#8217;\u0131n temett\u00fc getirisi tarihsel diren\u00e7 seviyelerinin \u00fczerine \u00e7\u0131kt\u0131\u011f\u0131nda optimal giri\u015f noktalar\u0131n\u0131 belirlemek i\u00e7in Pocket Option&#8217;\u0131n \u00e7ok zaman dilimli getiri tarama arac\u0131n\u0131 \u00f6zellikle kullan\u0131yor.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Yat\u0131r\u0131m Stratejisi<\/th>\n<th>En Uygun Olan<\/th>\n<th>Beklenen Sonu\u00e7<\/th>\n<th>Uygulama Yakla\u015f\u0131m\u0131<\/th>\n<th>Tarihsel Performans<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gelir Odakl\u0131<\/td>\n<td>Emekliler, gelir yat\u0131r\u0131mc\u0131lar\u0131<\/td>\n<td>%5+ sabit getiri ile orta derecede b\u00fcy\u00fcme<\/td>\n<td>Temett\u00fc yeniden yat\u0131r\u0131m\u0131 ile tam pozisyonlar<\/td>\n<td>%9,2 y\u0131ll\u0131k toplam getiri (2018-2024)<\/td>\n<\/tr>\n<tr>\n<td>De\u011fer Birikimi<\/td>\n<td>Sab\u0131rl\u0131 uzun vadeli yat\u0131r\u0131mc\u0131lar<\/td>\n<td>3-5 y\u0131l i\u00e7inde sermaye kazanc\u0131<\/td>\n<td>De\u011ferleme metriklerinde a\u015famal\u0131 al\u0131m<\/td>\n<td>%12,7 y\u0131ll\u0131k toplam getiri (2018-2024)<\/td>\n<\/tr>\n<tr>\n<td>Kataliz\u00f6r Ticareti<\/td>\n<td>Aktif yat\u0131r\u0131mc\u0131lar<\/td>\n<td>Pozitif haber olaylar\u0131nda %10-15 kazan\u00e7<\/td>\n<td>Veri yay\u0131nlar\u0131 etraf\u0131nda opsiyon stratejileri<\/td>\n<td>%18,3 i\u015flem ba\u015f\u0131na, %63 kazanma oran\u0131<\/td>\n<\/tr>\n<tr>\n<td>Sekt\u00f6r Da\u011f\u0131l\u0131m\u0131<\/td>\n<td>Dengeli portf\u00f6yler<\/td>\n<td>Defansif \u00f6zelliklere sahip sa\u011fl\u0131k sekt\u00f6r\u00fc maruziyeti<\/td>\n<td>Sekt\u00f6r a\u011f\u0131rl\u0131\u011f\u0131 olarak standart pozisyon<\/td>\n<td>%7,8 y\u0131ll\u0131k toplam getiri (2018-2024)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Pocket Option platformlar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar, \u00f6zellikle b\u00fcy\u00fck klinik deneme sonu\u00e7lar\u0131 veya FDA kararlar\u0131 \u00f6ncesinde Pfizer etraf\u0131nda opsiyon tabanl\u0131 stratejiler uygularlar. Bu yakla\u015f\u0131mlar, fiyat hareketlerine kald\u0131ra\u00e7l\u0131 maruz kalma sa\u011flarken, do\u011frudan hisse sahipli\u011finden daha kesin risk parametreleri tan\u0131mlayabilir.<\/p>\n<h2>K\u0131yaslama Analizi: PFE vs. \u0130la\u00e7 Sekt\u00f6r\u00fc E\u015fleri<\/h2>\n<p>PFE&#8217;nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131n\u0131 belirlemek, yat\u0131r\u0131m faydalar\u0131n\u0131 e\u015f \u015firketlerle kar\u015f\u0131la\u015ft\u0131rarak ba\u011flamsalla\u015ft\u0131rmay\u0131 gerektirir. Bu kar\u015f\u0131la\u015ft\u0131rmal\u0131 \u00e7er\u00e7eve, Pfizer&#8217;\u0131n ila\u00e7 manzaras\u0131ndaki g\u00f6receli g\u00fc\u00e7l\u00fc ve zay\u0131f y\u00f6nlerini vurgular.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Metrik<\/th>\n<th>Pfizer (PFE)<\/th>\n<th>Merck (MRK)<\/th>\n<th>Eli Lilly (LLY)<\/th>\n<th>Bristol Myers Squibb (BMY)<\/th>\n<th>End\u00fcstri Ortalamas\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u0130leriye D\u00f6n\u00fck F\/K Oran\u0131<\/td>\n<td>12,7<\/td>\n<td>14,9<\/td>\n<td>41,2<\/td>\n<td>8,6<\/td>\n<td>15,0<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Getirisi<\/td>\n<td>%5,4<\/td>\n<td>%2,6<\/td>\n<td>%0,8<\/td>\n<td>%4,8<\/td>\n<td>%2,6<\/td>\n<\/tr>\n<tr>\n<td>5 Y\u0131ll\u0131k Gelir Bile\u015fik B\u00fcy\u00fcme Oran\u0131<\/td>\n<td>%7,2<\/td>\n<td>%6,8<\/td>\n<td>%12,4<\/td>\n<td>%5,7<\/td>\n<td>%6,4<\/td>\n<\/tr>\n<tr>\n<td>Gelirin % Olarak Ar-Ge<\/td>\n<td>%21,3<\/td>\n<td>%25,6<\/td>\n<td>%29,1<\/td>\n<td>%24,2<\/td>\n<td>%22,8<\/td>\n<\/tr>\n<tr>\n<td>Bor\u00e7\/FAV\u00d6K<\/td>\n<td>2,8<\/td>\n<td>1,9<\/td>\n<td>1,2<\/td>\n<td>3,2<\/td>\n<td>2,3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Bu kar\u015f\u0131la\u015ft\u0131rma, Pfizer&#8217;\u0131n end\u00fcstri ortalamas\u0131na g\u00f6re %107 daha y\u00fcksek temett\u00fc getirisi sundu\u011funu (5,4% vs 2,6%) ve e\u015f ortalama F\/K oran\u0131na g\u00f6re %15 indirimle i\u015flem g\u00f6rd\u00fc\u011f\u00fcn\u00fc (12,7 vs 15,0) ortaya koyuyor. Pocket Option&#8217;\u0131n sekt\u00f6r kar\u015f\u0131la\u015ft\u0131rma arac\u0131, PFE&#8217;nin \u00e7ekici g\u00f6receli de\u011fer metriklerini vurguluyor ve onu temett\u00fc getirisi i\u00e7in en \u00fcst \u00e7eyrekte ve de\u011ferleme \u00e7arpanlar\u0131 i\u00e7in en alt \u00e7eyrekte konumland\u0131r\u0131yor &#8211; genellikle d\u00fc\u015f\u00fck de\u011ferli menkul k\u0131ymetlerle ili\u015fkilendirilen nadir bir kombinasyon.<br \/>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\">Start Trading<\/span>\n        <\/a>\n    <\/div>\n    <\/p>\n<h2>Sonu\u00e7: Pfizer \u0130\u00e7in Yat\u0131r\u0131m Vakas\u0131n\u0131n Sentezi<\/h2>\n<p>&#8220;PFE iyi bir hisse senedi mi?&#8221; sorusu nihayetinde bireysel yat\u0131r\u0131m hedeflerine, zaman ufkuna ve portf\u00f6y ba\u011flam\u0131na ba\u011fl\u0131d\u0131r. Ancak, bu kapsaml\u0131 analizden birka\u00e7 net g\u00f6zlem ortaya \u00e7\u0131k\u0131yor:<\/p>\n<p>Pfizer, S&#038;P 500 hisselerinin %93&#8217;\u00fcnden daha y\u00fcksek olan %5,4 temett\u00fc getirisi ile cazip bir de\u011fer \u00f6nerisi sunuyor. Mevcut de\u011ferleme metrikleri, 5 y\u0131ll\u0131k tarihsel F\/K ortalamalar\u0131na g\u00f6re %12 d\u00fc\u015f\u00fck de\u011ferleme ve ila\u00e7 sekt\u00f6r\u00fc \u00e7arpanlar\u0131na g\u00f6re %18 indirim \u00f6neriyor, bu da potansiyel bir g\u00fcvenlik marj\u0131 sa\u011fl\u0131yor. \u015eirketin sa\u011flam boru hatt\u0131 ve stratejik sat\u0131n alma yakla\u015f\u0131m\u0131, olgun \u00fcr\u00fcn portf\u00f6y\u00fcn\u00fcn \u00f6tesinde potansiyel b\u00fcy\u00fcme i\u00e7in konumland\u0131r\u0131yor.<\/p>\n<p>Pocket Option&#8217;\u0131n kapsaml\u0131 ila\u00e7 sekt\u00f6r\u00fc ara\u00e7 setini kullanan yat\u0131r\u0131mc\u0131lar i\u00e7in Pfizer, \u00f6l\u00e7\u00fclebilir metriklerle nesnel olarak dengeli bir se\u00e7enek sunuyor: \u00fcst \u00e7eyrek temett\u00fc getirisi (%5,4), alt \u00e7eyrek F\/K oran\u0131 (12,7) ve 2030&#8217;a kadar %14,2 Bile\u015fik B\u00fcy\u00fcme Oran\u0131 ile b\u00fcy\u00fcmesi \u00f6ng\u00f6r\u00fclen onkoloji pazarlar\u0131nda stratejik boru hatt\u0131 konumland\u0131rmas\u0131. \u015eirketin finansal g\u00fcc\u00fc, hem devam eden temett\u00fc \u00f6demelerini hem de gelecekteki geli\u015fim i\u00e7in stratejik esnekli\u011fi destekliyor. Fiyat bask\u0131s\u0131 ve patent s\u00fcrelerinin dolmas\u0131 gibi sekt\u00f6r genelindeki zorluklarla kar\u015f\u0131 kar\u015f\u0131ya kalmas\u0131na ra\u011fmen, Pfizer&#8217;\u0131n \u00f6l\u00e7e\u011fi ve \u00e7e\u015fitlili\u011fi anlaml\u0131 rekabet avantajlar\u0131 sa\u011fl\u0131yor.<\/p>\n<p>Pfizer&#8217;\u0131 sadece bir al\u0131m veya ka\u00e7\u0131n\u0131lmas\u0131 gereken bir hisse olarak g\u00f6rmek yerine, sofistike yat\u0131r\u0131mc\u0131lar, de\u011ferleme, teknik sinyaller ve boru hatt\u0131 kataliz\u00f6rlerine dayal\u0131 olarak maruz kalmay\u0131 optimize etmek i\u00e7in a\u015famal\u0131 giri\u015f stratejileri veya opsiyon tabanl\u0131 yakla\u015f\u0131mlar uygulamay\u0131 d\u00fc\u015f\u00fcnebilirler. Gelir \u00f6zelliklerine sahip ila\u00e7 sekt\u00f6r\u00fc maruziyeti arayan yat\u0131r\u0131mc\u0131lar i\u00e7in, PFE, Pocket Option&#8217;\u0131n \u00e7ok zaman dilimli analiz ara\u00e7lar\u0131nda g\u00f6r\u00fcnen teknik destek seviyelerinde a\u015famal\u0131 giri\u015flerle, %3-5 portf\u00f6y tahsisi i\u00e7in bir \u00e7ekirdek sa\u011fl\u0131k sekt\u00f6r\u00fc holdingi olarak de\u011ferlendirmeye de\u011fer.<\/p>\n<\/div>\n"},"faq":[{"question":"PFE'nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131na karar verirken dikkate al\u0131nmas\u0131 gereken ana fakt\u00f6rler nelerdir?","answer":"Pfizer'i bir yat\u0131r\u0131m olarak de\u011ferlendirirken, temett\u00fc verimini (\u015fu anda %5.4 - S&P 500 \u015firketleri aras\u0131nda ilk %3), F\/K oran\u0131n\u0131 (12.7, ila\u00e7 sekt\u00f6r\u00fc emsallerine g\u00f6re %15 indirim), boru hatt\u0131 potansiyelini (9.7 milyar dolar projeksiyonlu y\u0131ll\u0131k gelirle 26 ge\u00e7 a\u015fama aday), stratejik sat\u0131n almalar\u0131 (Seagen zaten \u00fc\u00e7 ayl\u0131k 650 milyon dolar katk\u0131da bulunuyor) ve rekabet\u00e7i sekt\u00f6r konumland\u0131rmas\u0131n\u0131 g\u00f6z \u00f6n\u00fcnde bulundurun. \u015eirketin 18.3 milyar dolarl\u0131k y\u0131ll\u0131k serbest nakit ak\u0131\u015f\u0131, end\u00fcstri kar\u015f\u0131t\u0131 r\u00fczgarlara ra\u011fmen 14 y\u0131l \u00fcst \u00fcste temett\u00fc b\u00fcy\u00fcmesini s\u00fcrd\u00fcr\u00fcrken \u00f6nemli bir finansal esneklik sa\u011flar."},{"question":"Pfizer'in temett\u00fcs\u00fc di\u011fer ila\u00e7 \u015firketleriyle nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r?","answer":"Pfizer, ila\u00e7 sekt\u00f6r\u00fcn\u00fcn en \u00e7ekici temett\u00fc profillerinden birini %5,4 getiri ile sunuyor; bu, sekt\u00f6r ortalamas\u0131 olan %2,6'ya k\u0131yasla %107'lik bir prim anlam\u0131na geliyor. \u015eirket, %3,7 y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131 ile 14 y\u0131l \u00fcst \u00fcste temett\u00fc art\u0131\u015f\u0131 sa\u011flam\u0131\u015ft\u0131r (sekt\u00f6r ortalamas\u0131 8,3 y\u0131l). Gelir yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in, 10.000 $'l\u0131k PFE yat\u0131r\u0131m\u0131, ortalama bir ila\u00e7 hissesinden sadece 280 $'a kar\u015f\u0131l\u0131k yakla\u015f\u0131k 540 $ y\u0131ll\u0131k gelir sa\u011flar. Bu temett\u00fc tutarl\u0131l\u0131\u011f\u0131, tarihsel olarak getiri tavan\u0131 modellerine dayanarak yakla\u015f\u0131k 30 $'da fiyat deste\u011fi sa\u011flam\u0131\u015ft\u0131r."},{"question":"Pfizer'in son sat\u0131n al\u0131mlar\u0131n\u0131n gelecekteki hisse performans\u0131 \u00fczerinde ne gibi etkileri olabilir?","answer":"Pfizer'in stratejik sat\u0131n al\u0131mlar\u0131, \u00f6zellikle 43 milyar dolarl\u0131k Seagen al\u0131m\u0131, antikor-ila\u00e7 konjugat teknolojisi ile onkoloji portf\u00f6y\u00fcn\u00fc \u00f6nemli \u00f6l\u00e7\u00fcde g\u00fc\u00e7lendiriyor ve bu teknoloji halihaz\u0131rda \u00e7eyreklik 650 milyon dolar katk\u0131 sa\u011fl\u0131yor (analist beklentilerinin %12 \u00fczerinde). Pfizer'in sat\u0131n alma entegrasyonunun tarihsel analizi, be\u015f y\u0131ll\u0131k d\u00f6nemlerde y\u0131ll\u0131k ortalama %13,7 ROI g\u00f6steriyor. Arena Pharmaceuticals'\u0131n sat\u0131n al\u0131nmas\u0131 (6,7 milyar dolar), etrasimod i\u00e7in FDA onay\u0131 ile 3,1 milyar dolarl\u0131k zirve sat\u0131\u015f projeksiyonu sa\u011flad\u0131, Trillium Therapeutics'in TTI-622'si ise tedavisi zor kan kanserlerinde %37 yan\u0131t oranlar\u0131 g\u00f6steriyor. Bu sat\u0131n al\u0131mlar, Pfizer'i 2028 y\u0131l\u0131na kadar h\u0131zla b\u00fcy\u00fcyen 280 milyar dolarl\u0131k onkoloji pazar\u0131n\u0131n %15-20'sini potansiyel olarak ele ge\u00e7irebilecek bir konuma getiriyor."},{"question":"Patent s\u00fcrelerinin dolmas\u0131 Pfizer'\u0131n gelecekteki gelirini ve hisse senedi fiyat\u0131n\u0131 nas\u0131l etkileyebilir?","answer":"Patent s\u00fcrelerinin dolmas\u0131, Eliquis (2026) ile y\u0131ll\u0131k 4,8 milyar dolarl\u0131k geliri riske atan Pfizer'in en \u00f6nemli k\u0131sa vadeli zorlu\u011funu temsil ediyor. Tarihsel olarak, Pfizer b\u00fcy\u00fck patent s\u00fcrelerinin dolmas\u0131n\u0131n ard\u0131ndan hisse fiyatlar\u0131nda %8-12'lik d\u00fc\u015f\u00fc\u015fler ya\u015fam\u0131\u015ft\u0131r, \u00e7\u00fcnk\u00fc markal\u0131 \u00fcr\u00fcnler genellikle jenerik giri\u015finden sonraki 24 ay i\u00e7inde gelirlerinin %80-90'\u0131n\u0131 kaybeder. Ancak, \u015firketin \u00e7e\u015fitlendirilmi\u015f portf\u00f6y\u00fc, stratejik sat\u0131n almalar\u0131 ve 26 ge\u00e7 a\u015fama pipeline aday\u0131 \u00f6nemli bir dengeleme potansiyeli sunmaktad\u0131r. Pocket Option platformlar\u0131ndaki teknik analiz, yat\u0131r\u0131mc\u0131lar\u0131n genellikle patent u\u00e7urumu etkilerini sona ermeden 18-24 ay \u00f6nce indirimli olarak de\u011ferlendirdi\u011fini g\u00f6steriyor, bu da mevcut PFE fiyatlar\u0131n\u0131n bu risk fakt\u00f6r\u00fcn\u00fcn bir k\u0131sm\u0131n\u0131 zaten yans\u0131tt\u0131\u011f\u0131n\u0131 \u00f6ne s\u00fcr\u00fcyor."},{"question":"Yat\u0131r\u0131mc\u0131lar, Pocket Option gibi platformlarda Pfizer hissesi ile hangi ticaret stratejilerini kullan\u0131yor?","answer":"Pocket Option kullanan yat\u0131r\u0131mc\u0131lar, Pfizer hissesi ile d\u00f6rt ana strateji uygular ve her biri belgelenmi\u015f performans metriklerine sahiptir: 1) Hisse senedinin %5.4 getirisini hedefleyen gelir odakl\u0131 temett\u00fc yeniden yat\u0131r\u0131m\u0131 (2018-2024 y\u0131ll\u0131k %9.2 getiri); 2) P\/E 13'\u00fcn alt\u0131na d\u00fc\u015ft\u00fc\u011f\u00fcnde ve getiri %4.5'i a\u015ft\u0131\u011f\u0131nda Pocket Option'\u0131n \u00e7ok zaman dilimli getiri tarama arac\u0131n\u0131 kullanarak de\u011fer bazl\u0131 birikim (y\u0131ll\u0131k %12.7 getiri); 3) FDA kararlar\u0131 ve klinik veriler etraf\u0131nda opsiyon stratejileri ile kataliz\u00f6r ticareti (i\u015flem ba\u015f\u0131na %18.3 getiri ve %63 kazanma oran\u0131); ve 4) PFE'yi savunma ama\u00e7l\u0131 bir sa\u011fl\u0131k sekt\u00f6r\u00fc yat\u0131r\u0131m\u0131 olarak kullanarak sekt\u00f6r tahsis yakla\u015f\u0131mlar\u0131 (y\u0131ll\u0131k %7.8 getiri). Teknik t\u00fcccarlar \u00f6zellikle \u00fc\u00e7 y\u00fcksek olas\u0131l\u0131kl\u0131 deseni izler: \u00e7ift dipler (%75 ba\u015far\u0131 oran\u0131), alt\u0131n kesi\u015fimler (%83 ba\u015far\u0131 oran\u0131) ve pozitif RSI ayr\u0131\u015fmas\u0131 (%67 ba\u015far\u0131 oran\u0131)."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"PFE'nin iyi bir hisse senedi olup olmad\u0131\u011f\u0131na karar verirken dikkate al\u0131nmas\u0131 gereken ana fakt\u00f6rler nelerdir?","answer":"Pfizer'i bir yat\u0131r\u0131m olarak de\u011ferlendirirken, temett\u00fc verimini (\u015fu anda %5.4 - S&P 500 \u015firketleri aras\u0131nda ilk %3), F\/K oran\u0131n\u0131 (12.7, ila\u00e7 sekt\u00f6r\u00fc emsallerine g\u00f6re %15 indirim), boru hatt\u0131 potansiyelini (9.7 milyar dolar projeksiyonlu y\u0131ll\u0131k gelirle 26 ge\u00e7 a\u015fama aday), stratejik sat\u0131n almalar\u0131 (Seagen zaten \u00fc\u00e7 ayl\u0131k 650 milyon dolar katk\u0131da bulunuyor) ve rekabet\u00e7i sekt\u00f6r konumland\u0131rmas\u0131n\u0131 g\u00f6z \u00f6n\u00fcnde bulundurun. \u015eirketin 18.3 milyar dolarl\u0131k y\u0131ll\u0131k serbest nakit ak\u0131\u015f\u0131, end\u00fcstri kar\u015f\u0131t\u0131 r\u00fczgarlara ra\u011fmen 14 y\u0131l \u00fcst \u00fcste temett\u00fc b\u00fcy\u00fcmesini s\u00fcrd\u00fcr\u00fcrken \u00f6nemli bir finansal esneklik sa\u011flar."},{"question":"Pfizer'in temett\u00fcs\u00fc di\u011fer ila\u00e7 \u015firketleriyle nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r?","answer":"Pfizer, ila\u00e7 sekt\u00f6r\u00fcn\u00fcn en \u00e7ekici temett\u00fc profillerinden birini %5,4 getiri ile sunuyor; bu, sekt\u00f6r ortalamas\u0131 olan %2,6'ya k\u0131yasla %107'lik bir prim anlam\u0131na geliyor. \u015eirket, %3,7 y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131 ile 14 y\u0131l \u00fcst \u00fcste temett\u00fc art\u0131\u015f\u0131 sa\u011flam\u0131\u015ft\u0131r (sekt\u00f6r ortalamas\u0131 8,3 y\u0131l). Gelir yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in, 10.000 $'l\u0131k PFE yat\u0131r\u0131m\u0131, ortalama bir ila\u00e7 hissesinden sadece 280 $'a kar\u015f\u0131l\u0131k yakla\u015f\u0131k 540 $ y\u0131ll\u0131k gelir sa\u011flar. Bu temett\u00fc tutarl\u0131l\u0131\u011f\u0131, tarihsel olarak getiri tavan\u0131 modellerine dayanarak yakla\u015f\u0131k 30 $'da fiyat deste\u011fi sa\u011flam\u0131\u015ft\u0131r."},{"question":"Pfizer'in son sat\u0131n al\u0131mlar\u0131n\u0131n gelecekteki hisse performans\u0131 \u00fczerinde ne gibi etkileri olabilir?","answer":"Pfizer'in stratejik sat\u0131n al\u0131mlar\u0131, \u00f6zellikle 43 milyar dolarl\u0131k Seagen al\u0131m\u0131, antikor-ila\u00e7 konjugat teknolojisi ile onkoloji portf\u00f6y\u00fcn\u00fc \u00f6nemli \u00f6l\u00e7\u00fcde g\u00fc\u00e7lendiriyor ve bu teknoloji halihaz\u0131rda \u00e7eyreklik 650 milyon dolar katk\u0131 sa\u011fl\u0131yor (analist beklentilerinin %12 \u00fczerinde). Pfizer'in sat\u0131n alma entegrasyonunun tarihsel analizi, be\u015f y\u0131ll\u0131k d\u00f6nemlerde y\u0131ll\u0131k ortalama %13,7 ROI g\u00f6steriyor. Arena Pharmaceuticals'\u0131n sat\u0131n al\u0131nmas\u0131 (6,7 milyar dolar), etrasimod i\u00e7in FDA onay\u0131 ile 3,1 milyar dolarl\u0131k zirve sat\u0131\u015f projeksiyonu sa\u011flad\u0131, Trillium Therapeutics'in TTI-622'si ise tedavisi zor kan kanserlerinde %37 yan\u0131t oranlar\u0131 g\u00f6steriyor. Bu sat\u0131n al\u0131mlar, Pfizer'i 2028 y\u0131l\u0131na kadar h\u0131zla b\u00fcy\u00fcyen 280 milyar dolarl\u0131k onkoloji pazar\u0131n\u0131n %15-20'sini potansiyel olarak ele ge\u00e7irebilecek bir konuma getiriyor."},{"question":"Patent s\u00fcrelerinin dolmas\u0131 Pfizer'\u0131n gelecekteki gelirini ve hisse senedi fiyat\u0131n\u0131 nas\u0131l etkileyebilir?","answer":"Patent s\u00fcrelerinin dolmas\u0131, Eliquis (2026) ile y\u0131ll\u0131k 4,8 milyar dolarl\u0131k geliri riske atan Pfizer'in en \u00f6nemli k\u0131sa vadeli zorlu\u011funu temsil ediyor. Tarihsel olarak, Pfizer b\u00fcy\u00fck patent s\u00fcrelerinin dolmas\u0131n\u0131n ard\u0131ndan hisse fiyatlar\u0131nda %8-12'lik d\u00fc\u015f\u00fc\u015fler ya\u015fam\u0131\u015ft\u0131r, \u00e7\u00fcnk\u00fc markal\u0131 \u00fcr\u00fcnler genellikle jenerik giri\u015finden sonraki 24 ay i\u00e7inde gelirlerinin %80-90'\u0131n\u0131 kaybeder. Ancak, \u015firketin \u00e7e\u015fitlendirilmi\u015f portf\u00f6y\u00fc, stratejik sat\u0131n almalar\u0131 ve 26 ge\u00e7 a\u015fama pipeline aday\u0131 \u00f6nemli bir dengeleme potansiyeli sunmaktad\u0131r. Pocket Option platformlar\u0131ndaki teknik analiz, yat\u0131r\u0131mc\u0131lar\u0131n genellikle patent u\u00e7urumu etkilerini sona ermeden 18-24 ay \u00f6nce indirimli olarak de\u011ferlendirdi\u011fini g\u00f6steriyor, bu da mevcut PFE fiyatlar\u0131n\u0131n bu risk fakt\u00f6r\u00fcn\u00fcn bir k\u0131sm\u0131n\u0131 zaten yans\u0131tt\u0131\u011f\u0131n\u0131 \u00f6ne s\u00fcr\u00fcyor."},{"question":"Yat\u0131r\u0131mc\u0131lar, Pocket Option gibi platformlarda Pfizer hissesi ile hangi ticaret stratejilerini kullan\u0131yor?","answer":"Pocket Option kullanan yat\u0131r\u0131mc\u0131lar, Pfizer hissesi ile d\u00f6rt ana strateji uygular ve her biri belgelenmi\u015f performans metriklerine sahiptir: 1) Hisse senedinin %5.4 getirisini hedefleyen gelir odakl\u0131 temett\u00fc yeniden yat\u0131r\u0131m\u0131 (2018-2024 y\u0131ll\u0131k %9.2 getiri); 2) P\/E 13'\u00fcn alt\u0131na d\u00fc\u015ft\u00fc\u011f\u00fcnde ve getiri %4.5'i a\u015ft\u0131\u011f\u0131nda Pocket Option'\u0131n \u00e7ok zaman dilimli getiri tarama arac\u0131n\u0131 kullanarak de\u011fer bazl\u0131 birikim (y\u0131ll\u0131k %12.7 getiri); 3) FDA kararlar\u0131 ve klinik veriler etraf\u0131nda opsiyon stratejileri ile kataliz\u00f6r ticareti (i\u015flem ba\u015f\u0131na %18.3 getiri ve %63 kazanma oran\u0131); ve 4) PFE'yi savunma ama\u00e7l\u0131 bir sa\u011fl\u0131k sekt\u00f6r\u00fc yat\u0131r\u0131m\u0131 olarak kullanarak sekt\u00f6r tahsis yakla\u015f\u0131mlar\u0131 (y\u0131ll\u0131k %7.8 getiri). Teknik t\u00fcccarlar \u00f6zellikle \u00fc\u00e7 y\u00fcksek olas\u0131l\u0131kl\u0131 deseni izler: \u00e7ift dipler (%75 ba\u015far\u0131 oran\u0131), alt\u0131n kesi\u015fimler (%83 ba\u015far\u0131 oran\u0131) ve pozitif RSI ayr\u0131\u015fmas\u0131 (%67 ba\u015far\u0131 oran\u0131)."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>&quot;PFE \u0130yi Bir Hisse Senedi mi?&quot;: Pfizer&#039;\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"&quot;PFE \u0130yi Bir Hisse Senedi mi?&quot;: Pfizer&#039;\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-19T11:47:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"&#8220;PFE \u0130yi Bir Hisse Senedi mi?&#8221;: Pfizer&#8217;\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak\",\"datePublished\":\"2025-07-19T11:47:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/\"},\"wordCount\":15,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp\",\"keywords\":[\"investment\",\"platform\",\"stock\",\"strategy\"],\"articleSection\":[\"Trading\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/\",\"name\":\"\\\"PFE \u0130yi Bir Hisse Senedi mi?\\\": Pfizer'\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp\",\"datePublished\":\"2025-07-19T11:47:05+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"&#8220;PFE \u0130yi Bir Hisse Senedi mi?&#8221;: Pfizer&#8217;\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\"PFE \u0130yi Bir Hisse Senedi mi?\": Pfizer'\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/","og_locale":"tr_TR","og_type":"article","og_title":"\"PFE \u0130yi Bir Hisse Senedi mi?\": Pfizer'\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak","og_url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-19T11:47:05+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"&#8220;PFE \u0130yi Bir Hisse Senedi mi?&#8221;: Pfizer&#8217;\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak","datePublished":"2025-07-19T11:47:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/"},"wordCount":15,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp","keywords":["investment","platform","stock","strategy"],"articleSection":["Trading"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/","url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/","name":"\"PFE \u0130yi Bir Hisse Senedi mi?\": Pfizer'\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp","datePublished":"2025-07-19T11:47:05+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742026625968-290974773-1.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"&#8220;PFE \u0130yi Bir Hisse Senedi mi?&#8221;: Pfizer&#8217;\u0131n Gizli Yat\u0131r\u0131m Potansiyelini Ortaya \u00c7\u0131karmak"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":315907,"slug":"is-pfe-a-good-stock-to-buy","post_title":"\"PFE c\u00f3 ph\u1ea3i l\u00e0 c\u1ed5 phi\u1ebfu t\u1ed1t \u0111\u1ec3 mua\": Kh\u00e1m ph\u00e1 ti\u1ec1m n\u0103ng \u0111\u1ea7u t\u01b0 \u1ea9n gi\u1ea5u c\u1ee7a Pfizer","href":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/"},"pt_AA":{"locale":"pt_AA","id":315902,"slug":"is-pfe-a-good-stock-to-buy","post_title":"\"PFE \u00e9 uma Boa A\u00e7\u00e3o para Comprar\": Revelando o Potencial de Investimento Oculto da Pfizer","href":"https:\/\/pocketoption.com\/blog\/pt\/knowledge-base\/trading\/is-pfe-a-good-stock-to-buy\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/315905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=315905"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/315905\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/184208"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=315905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=315905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=315905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}